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1.1. Biomaterials in Drug Delivery 
 
A biomaterial as by definition is „a material intended to interface with biological 
systems to evaluate, treat, augment or replace any tissue, organ or function of the 
body”[1]. Biocompatibility is the essential characteristic of a biomaterial, and it is 
described as “the ability of a material to perform with an appropriate host response 
in a specific situation” [1]. Biomaterials in general have attracted increasing 
interest in the pharmaceutical industry, and a wide range of their applications 
have been described in the past decades [2]. One of the most remarkable 
applications is a controlled drug delivery system (DDS) using biocompatible 
polymers [3, 4]. In these DDS, drugs are incorporated into a polymeric material 
with the release rate of the drug being determined by the properties of the drug-
polymer system and by the surrounding environment [5].  
In the past, constant rate release kinetics were obtained by incorporating the drug 
in polymeric matrices like poly(ethylen-co-vinyl acetate) (Ocusert®, 
Progestesert®) and silicone rubbers (Norplant®, Vaginal Ring®) [6]. Another 
strategy was the use of a rate controlling polymeric membrane (Implanon®[7], 
Oros®[8], Duros®[9]). Furthermore, most of the transdermal therapeutic systems 
(TTS), are designed to release the drug at a constant rate [10]. The above 
mentioned DDS are able to release the drug in an almost zero order release 
kinetic, which is particularly interesting due to its capacity to control the plasma 
drug concentration. In addition to this, they can reduce the administration 
frequency improving patient compliance.  
When a DDS is implanted, the biomaterial that composes it should not react 
adversely with the biological surrounding and the functionality of the tissue 
should not be compromised [11-13]. On top of this, it should also fulfil the 
requirements described by ISO 10993 (Biological evaluation of medical devices 
[14]). Another desired characteristic in designing an implantable DDS is the 
biodegradation of the polymer that composes it. Two important examples of 
biodegradable materials used in drug release technology are poly(lactic-co-
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glycolic acid) (Zoladex® [15], Enantone Depot®) and polyanhydrides (Gliadel® 
Wafer [16]). Since the launch of Zoladex® (1989) less than ten clinical products 
able to deliver peptides and proteins have been developed [17].  
Poly(lactic-co-glycolic acid) (PLGA) polymers have been extensively investigated 
[18-20]. Their drug release profile is often described as a three-phase profile [21-
23]. Phase I is characterized by a burst where the non-encapsulated drug or the 
drug loaded on the surface of the DDS is released. Phase II consists of a slow 
constant release, where the drug needs to diffuse through the polymeric matrix 
before being released. Phase III is considered as a second burst, where the drug is 
released quickly due to the erosion of the PLGA matrix. In general, the 
encapsulated drug can diffuse out of the PLGA polymeric matrix due to: (I) 
diffusion through water-filled pores, (II) diffusion through the polymer, (III) 
osmotic pumping, and finally (IV) erosion [23]. The tissue reaction to the presence 
of this family of polymers has been covered substantially in literature [24-26]. 
PLGA particles can cause a body inflammation response that mainly depends on 
particle size, tissue type, and finally the nature of the polymer [13, 25, 27].  
In spite of the frequent use of PLGA co-polymers in the pharmaceutical industry, 
some negative aspects of this material have been reported in the past years, 
especially with regards to the encapsulation and delivery of peptides and protein 
[19, 28]. The manufacturing process of PLGA-based DDS has a major impact on the 
drug delivery system characteristics [28, 29]. For instance, during the process the 
biologic active ingredient can undergo denaturation and aggregation due to its 
instability at the water to organic solvent interface [28, 30, 31]. Moreover, the 
shear force applied to homogenize the primary emulsion during preparation of 
the particles can denature proteins and peptides as well [32]. Protein and peptide 
stability is particularly important, since aggregation not only decreases the drug’s 
activity but it can also lead to toxicity [33, 34]. Another reported negative aspect 
of PLGA drug delivery systems is the drug release profile, where often an 
incomplete release [35-38] or high bursts [39-42] can be observed. DDS that are 
made of PLGA which are currently available commercially are listed in Table 1.  
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Table 1: Marketed PLGA-based products, November 2016.   
Commercial Name Form 
Active 
Ingredient 
Application Company 
Lupron Depot® Particles Leuprolide 1-, 3-, 4-, 6-Month 
Takeda, 
Abbott 
Suprecur® MP Particles Buserelin  Monthly Sanofi 
Enantone® Particles Leuprorelin Monthly Takeda 
Zoladex®  Implant Goserelin 1-, 3-Month 
Astra 
Zeneca 
Sandostatin LAR® Particles Octreotid Monthly Novartis 
Profact® Depot Implant Buserelin  2-, 3-Month Sanofi 
Decapeptyl® SR Particles Triptorelin 1-, 3-Month Debiopharm 
Arestin™ Particles Minocyclin 2-Week OraPharma 
Risperdal® Consta™ Particles Risperidon 2-Week Janssen 
Eligard®  Liquid Leuprorelin 1-, 3-, 4-, 6-Month Astellas  
Vivitrol™ Particles Naltrexon Monthly Alkermes 
Leuprone® Implant Leuprorelin 3-Month Hexal 
Somatuline® LA Particles Lanreotide 2-Week Ipsen 
Trelstar™ Depot Particles Triptorelin Monthly Debiopharm 
Bydureon® Particles Exenatide Weekly 
Astra 
Zeneca 
Salvacyl® Particles Triptorelin 3-Month Ipsen 
Ozurdex® Implant Dextamethasone Monthly Allergan 
  
For these reasons, despite the extensive use of biomaterials in medical care, the 
research on polymers capable to minimize the negative foreign body reaction 
induced by its implantation is still a relevant topic [43, 44]. Moreover, obtaining 
the desired drug release profile remains a particular challenge. Even though there 
are many drug delivery systems already in the market, the incorporation of 
therapeutic biomolecules and their controlled release from a DDS is still a 
demanding task. Biologics represent a new therapeutic drug class and are 
particularly difficult to formulate into a stable drug product [45]. This is why the 
research of new biomaterials and new product designs can be considered a 
necessary focus for the development of next generation drug delivery systems.  
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1.2. Rational for Investigating Spider Silk as 
Biomaterial 
 
Among all the above mentioned polymers, spider silk proteins are exceptional 
natural materials when it comes to their mechanical properties [46-48], 
biocompatibility, and hypoallergenicity [49-52]. Spider silk has been used for 
medical purposes since ancient history. For instance, it was applied in Roman and 
medieval dermatological practices to facilitate open wound healing and halt 
bleeding [53, 54]. In the past, natural spider silk fibres have been tested as 
alternative microsurgical suture [55, 56]. Furthermore spider silk proteins were 
investigated as scaffold for nerve regeneration [57, 58]. In the modern ages the 
use of this outstanding material has been limited to research purposes. Product 
development has been disregarded due to the many difficulties encountered in 
farming spiders [59, 60]. This specific drawback has been addressed in the past 
years, through a method able to efficiently produce different recombinant spider 
silk proteins in Escherichia coli [61-63]. Recombinant spider silk proteins (RSSPs) 
are hydrophobic and slowly biodegrading biopolymers that unify the required 
properties for a drug delivery system [64]. RSSPs can be used to encapsulate and 
release a various range of active molecules including genes for tumor targeted 
delivery, enzymes and drugs [65-70]. One of the most interesting recombinant 
spider silk proteins is the protein eADF4(C16) [46]. This engineered protein 
composes primarily the natural spider protein ADF-4 produced by the spider 
Araneus diadematus (the common European garden spider). In one recent study 
[71], medical grade silicone implants have been coated with this recombinant 
spider silk protein. During an in vivo study using Sprague-Dawley rats as models, 
it was reported that eADF4(C16) coatings were able to reduce post-operative 
inflammation after inserting medical grade silicone implants in the animals [71]. 
As a consequence of inhibiting fibroblast proliferation and the synthesis of 
collagen I, the capsular fibrosis formation was reduced. Hence, the 
biocompatibility of eADF4(C16) was proven. The use of eADF4(C16) proteins as a 
polymeric matrix offers several advantages. Among these are its biocompatibility 
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[71], as well as the ability to be naturally degraded in the human body by 
proteases, leading to non-toxic degradation products (amino acids), and avoiding 
any additional surgery to remove the DDS [72].  
 
1.3. Spider Silk Proteins 
 
In nature, over 34000 species of spiders have been identified [73]. Each of them is 
able to produce several task specific silks with diverse mechanical properties [50, 
74-76]. Spider silk is characterized by outstanding mechanical properties [50, 77]. For 
instance major ampullate silk has a tensile strength comparable with the one of 
Kevlar fibers (4 x 109 N/m2 [73]). Furthermore, one single spider can produce and 
store up to seven different silk proteins in as many glands [78]. Spiders are 
notorious for their talent in building spider webs, which are composed by various 
silk proteins. The two main types of silk are the ones produced in the major and 
minor ampullate glands [49]. The first silk type is called dragline silk and it is 
characterized by high tensile strength since it is used by the spider to get away 
from potential enemies and furthermore it composes the frame of the spider web 
[73].  
Minor ampullate silk supports the web during its manufacture [79]. Other web 
threads are composed by flagelliform silk. These particular threads are covered by 
additional silk and other material in order to become sticky and are used for 
catching prays in the capture core threads of the spider web [80]. Finally, spiders 
produce specific silks to wrap their eggs and to conserve the food [80]. 
The primary amino acid structure of spider silk proteins is characterized by 
repetitive units. Within the amino acid sequence it is possible to identify the 
following functional parts: 
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1) The unit GPGXX, which is forming the β-turn spiral that is responsible for 
the outstanding elasticity properties of flagelliform silk [73, 81] 
2) An or GAn are alanine rich motifs, which contain 6-9 alanine amino acids 
forming crystalline β-sheets, fundamental for tensile strength [82, 83]. Proteins 
composing dragline threads present alanine rich motives. leading to the high 
strength that characterizes draglines [84, 85]. On the contrary, flagelliform silk 
does not contain this unit 
3) GGX is a glycine rich element which forms 31-helical units connecting the 
different crystalline regions (the β-sheet stacks) with each other. This particular 
structure is responsible for the elasticity proprieties of the dragline and 
flagelliform silks [86-88] 
4) Spacers: contain charged groups and separate the repetitive peptide units 
into cluster [73] 
5) NR: non repetitive regions at the amino- and carboxyl-termini of the 
proteins [61, 89] 
 
One of the most studied dragline thread is the one produced by the spider Araneus 
Diadematus (the common European garden cross spider). This dragline is mainly 
composed by two silk proteins: ADF-4 and ADF-3 (ADF stands for Araneus 
Diademaus Fibroin) [90, 91]. The molecular ratio between ADF-4 and ADF-3 is 3 
to 2 [92]. ADF-3 and ADF-4 have a similar amino acid sequences, but different 
water solubility. ADF-3 is soluble at high concentrations [93], in contrast, ADF-4 is 
almost water insoluble [94]. 
The natural spider silk assembly process (into thread) is characterized by a liquid-
solid phase transition and structural changes of the proteins [48].  
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Spider dragline silk proteins are produced by cells located in the epithelium of 
spider´s glands [95]. The proteins are then stored in the dope of the gland at high 
concentrations (up to 50% w/w without aggregation [73]). It is assumed that due 
to the amphiphilic nature of silk proteins, these are not arranged in a defined 
secondary structure inside the gland, but they are mostly organized into micelles 
[96, 97]. The auto-assembly process takes place in the spinning duct. The final 
fibers are rich in β-sheet crystallites aligned in parallel to the long axis of the fiber. 
The following physical and biochemical factors are responsible for the assembly 
process: 
 
1) pH changes from 7.2 in the glands to 6.3 in the spinning duct [98, 99] 
2) Ionic composition changes inside the duct: the chaotropic ions such as 
sodium and chloride are exchanged by the more kosmotropic ions like phosphate 
and potassium [98] 
3) The protein concentration increases in the distal part of the duct [100] 
4) At the end the viscous protein solution is subjected to increasing 
elongational flow and shear forces [96, 101] 
 
It has been suggested that the formation of colloidal aggregates is fundamental for 
the formation of the fiber in the spinning duct [102]. These particles are in the 
micrometre range and assemble together due to the applied shear forces. This is in 
accordance with the model described for assembly process of silks produced by 
the bombix mori worm [97, 103]. 
 
 
 
 
 
20 
 
 
1.4. The Recombinant Spider Silk Protein eADF4(C16) 
 
The production of recombinant spider silk proteins is complicated by several 
aspects such as the highly repetitive units of the genes, the length of the constructs 
(silk genes are very large, up to 15 Mbp) and finally the specific codon usage of 
spiders [104]. AMSilk GmbH (Martinsried, Germany) was one of the first company 
that successfully produced recombinant spider silk proteins.  
AMSilk has developed a unique process for producing spider silk proteins in 
industrial scale. This technology is based on the research of Prof. Thomas Scheibel. 
His group created engineered synthetic spider DNA leading to the production of 
spider silk-like proteins in E. coli [105, 106]. The production of recombinant 
spider silk proteins opened a new range of possibilities, including the opportunity 
to specifically modify the primary structure of these biopolymers and design a 
new protein with an enlarged functionality portfolio [46]. For instance, cell 
binding motifs (such as the integrin recognition sequence RDG) can be 
incorporated increasing cell adhesion and proliferation on scaffolds containing the 
modified recombinant spider silk protein [107-111]. Another example is the 
incorporation of a silver binding peptide or the human antimicrobial peptide NHP-
2, leading to hybrid silk films showing antimicrobial activities [112-114]. 
Ultimately, this technology enables the design of tailor-made recombinant spider 
silk proteins.  
Today AMSilk is the first industrial supplier of synthetic silk biopolymers, with a 
distribution network across Europe and South Korea. Recently (November 2016) 
the sport company Adidas announced a new performance shoe using Biosteel® 
fiber from AMSilk.  
Spider silk proteins can assemble in several stable morphological shapes, 
including particles, hydrogels, foams, films, and non-woven meshes [101, 107, 
109, 115-121].  
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One of the most promising spider silk proteins produced from AMSilk is the 
recombinant protein eADF4(C16) (also called C16 or SSP1). Its protein structure is 
based on the natural spider protein ADF-4 and comprises 16 repeats of the 
following sequence:  
 
(GSSAAAAAAAASGPGGYGPENQGPSGPGGYGPGGP)16 
 
 
It is possible to identify the same amino acid clusters described in paragraph 1.3 
within the primary structure. These units are correlated with the formation of 
distinct secondary structures which are ultimately responsible for the mechanical 
properties of the recombinant silk protein [61, 73, 81-89]. Figure 1 shows these 
amino acid clusters and their functionality. 
 
 
Figure 1: Primary structure of the recombinant protein eADF(C16). Highlighted with a 
dotted line is the functional group GPGXX, in black the group An, and finally in grey the 
unit GGX. 
 
The following table is intended to highlight the differences between the 
recombinant spider silk protein eADF4(C16) and the natural spider silk protein 
ADF4. 
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Table 2: Selected characteristics of the natural spider silk protein ADF4 and the 
engineered recombinant spider silk protein eADF4(C16) [61]. 
 
 ADF-4 eADF4(C16) 
Molecular mass (kDa) 34.9 47.7 
Extinction coefficient276 nm 
(M-1cm-1) 
nd 46400 
No. of charged amino acid 
residues (positive/negative) 
2/6 0/16 
Mean hydropathicity -0.075 -0.464 
Solubility (% w/v) <1 8 
 
The recombinant protein eADF4(C16) has a higher molecular mass and solubility 
than the natural protein ADF-4. Furthermore, the number of negatively charged 
amino acid residues is more than duplicated in comparison to the native protein 
ADF-4. 
The assembly process of the protein eADF4(C16) into fibrils has been recently 
investigated [122-124]. According to the described model, the polyalanine motifs 
within the primary structure are the key that triggers the auto-assembly process. 
The conversion from intrinsically disordered protein monomers to partially folded 
β-sheet rich monomers takes place after defined stimuli (such as: kosmotropic 
ions, temperature, or high protein concentration). These partially folded 
monomers further assemble into nuclei which lead to fibril formation after 
addition of other disordered monomers. The nucleation-step is considered to be 
the rate-limited one. Hydrogen bonds formation during β-sheet rearrangement 
and hydrophobic interactions are the major forces involved [122]. 
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1.5. Spider Silk Films 
 
Spider silk matrices can be produced through a large number of different 
techniques as recently reported by Borkner et al. [125]. The list of technologies 
that can be employed include: dip or spin coating [71, 126-128], layer-by-layer 
deposition [129], Langmuir-Blodgett deposition [130, 131], electrospinning [132-
137], electrophoretic deposition [138-140], and finally lithography [141, 142]. 
However, the most adopted method to cast spider silk films remains the solvent 
evaporation technique [46, 72, 143-147]. Evaporation of the solvent yields a silk 
film that is formed via non-covalent intermolecular interactions [48]. The 
properties of the resulting film are mainly determined by two components: the 
secondary structure of the assembled protein and the macroscopic structure, 
which provides the material’s interface with its environment [59]. The secondary 
structure is determined or influenced by the primary structure of the protein, the 
solvent and the type of post-treatment. Silk films can be structurally or chemically 
modified by subsequent post-treatments [146]. Spider silk protein films are 
commonly formed by a protein solution in water, hexafluoro-2-propanol (HFIP), 
formic acid, or trifluoroacetic acid [73, 107]. 
Films casted from aqueous solution mainly consist of random coil structures 
[148], whereas films from HFIP solutions show α-helix rich structures [147, 149], 
and films from formic acid solutions are mainly composed of β-sheet structures 
[107, 150]. Films rich in β-sheet structure are water insoluble [107]. Post-
treatments of water soluble films with dehydrating agents like alcohols, or 
kosmotropic ions, can result in water-insoluble films [107]. These post-treatments 
allow a transition from random coil/α-helical structures to higher content of β-
sheet crystals of about 70-80 Å [146].  
In a recent work, the influence of the substrate whereon the film is cast was 
investigated [151]. It was shown that a glass template surface leads to less content 
of β-sheets in comparison to polystyrene (PS) and polytetrafluorethylen (Teflon). 
Furthermore it was observed that it was easier to peel off spider silk films from 
 
24 
 
hydrophobic surfaces. Microphase separation has been already described for 
dragline silk and RSSPs [102, 115]. In this case the authors reported different 
microphase separations related to the nature of the template. Hydrophobic 
surfaces led to coatings with high amount of β-sheet structures where the 
hydrophilic areas (random coil and helical units) were distributed in the 
hydrophobic matrix. On the contrary, in the case of films cast on a hydrophilic 
surface, the matrix was mostly composed by random coil and helical structures 
while the hydrophobic areas (β-sheets) were dispersed within the matrix [151].  
Solubility of HFIP-based spider silk films, was investigated by Slotta et al. [147]. In 
this work films were incubated respectively in water, 8 M urea, 6 M guanidinium 
chloride (GdmCl) and finally 6 M guanidinium thiocyanate (GdmSCN). Films were 
soluble in water, but after post-treatment with methanol they became water 
insoluble. Furthermore, methanol-processed eADF4(C16) films were also 
insoluble in urea and GdmCl. Only GdmSCN was able to unfold the proteins 
composing the film matrix and therefore dissolve the spider silk films again. 
Junghans et al. [126] analyzed the properties of several silk layers composed 
respectively by: recombinant spider silk-ELP fusion protein SO1-ELP, recombinant 
spider silk protein AQ24NR3, and eADF4(C16). After microhardness testing, they 
concluded that only the eADF4(C16) films combined high hardness with elasticity 
comparable to technical plastics (PET and PEI).  
Spiess at al. [145] cast spider silk films using buffers, formic acid and HFIP. After 
investigating these films by thermal gravimetric analysis (TGA) and differential 
scanning calorimetry (DSC), they concluded that the thermal stability was not 
affected by the solvent used in the casting solution. On the contrary, mechanical 
properties were different. Films cast with formic acid showed a higher tensile 
strength, while HFIP-based films showed the higher elongation at break. Buffer-
based films were the most delicate. Moreover, they observed different β-sheet 
content in different areas of the same water-based film. 
After film processing it is possible to covalently couple small and large molecules 
on the film surface. In one example, spider silk films were activated with 1-ethyl-
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3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysulfosuccinimide 
(NHS). Films were then incubated with a solution of fluorescein or β-galactosidase 
[152].  
Alternatively, it is also feasible to produce a variation of the protein eADF4(C16) 
containing a single cysteine residue in the primary structure [107]. Films cast with 
this engineered silk protein showed similar properties compared to films cast 
with the original protein [107]. This specific functionalization can be used for 
controlled coupling using the free thiol groups presented on the film surface.  
In the past, drug loading and release of both small molecules and proteins have 
been studied for spider silk particles [65-67, 69]. In a recent work, films composed 
by eADF4(C16) or eADF4(C16) blended with a polymer, polycaprolactone (PCL) 
or thermoplastic polyurethane (TPU), were prepared using a HFIP-based casting 
solution [143]. Films were then post-treated with methanol to achieve water 
insolubility. These silk layers were loaded with small molecules (methyl violet or 
ethacridine lactate), and the described release profiles where affected by the film 
composition and by the presence of elastase. Films composed only by spider silk 
released more model drug and in general the presence of the enzyme slightly 
increased the release [143].  
More recently, using the same manufacturing process new films were obtained by 
blending eADF4(C16) proteins with polybutylene terephthalate (PBT) or 
poly(butylene terephthalate-co-poly(alkyleneglycol) terephthalate) (PBTAT) 
[153]. These films were mineralized with calcium ions and tested as scaffolds for 
bone tissue regeneration. In this study the biocompatibility of the films with both 
fibroblasts and human mesenchymal stem cells was assessed. Fibroblast adhesion 
was observed to be higher on blended films than on pure eADF4(C16) films. In 
addition, calcium mineralized PBTAT-50 and PBTAT-75 films showed the best 
biocompatibility with stem cells where the higher alkaline phosphatase (ALP) 
activity was measured [153]. 
Cell adhesion was further investigated on different spider silk coated catheter 
polymers: polyurethane, polytetrafluoroethylene, and finally silicone [154]. In this 
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study, several cell types were taken into consideration, such as: keratinocytes, 
neuronal cells, myoblasts, and fibroblasts. In accordance with the previous work, 
Borkner at al. observed poor or no cell adhesion on RSSP coatings suggesting good 
biocompatibility of spider silk and its use in biomedical applications. 
As discussed in this chapter, in a near future spider silk films could be successfully 
employed as scaffolds for tissue engineering, artificial nerve construct, delivery 
system, diagnostics, biocompatible coating for biomedical device and implants 
[46, 125].  
 
1.6. Aim of the Thesis 
 
The aim of this research project was the development and characterization of 
water-based spider silk films composed of eADF4(C16) protein. When this work 
started, spider silk films were normally produced using organic solvents and little 
was known about casting films from a water solution. Furthermore their potential 
as a drug delivery system had not been yet investigated. Most of the interesting 
studies presented in paragraph 1.5 on spider silk films were done in parallel to 
this project by the Scheibel group. This thesis focused in the investigation of the 
application of water-based eADF4(C16) films as DDS for both small molecular 
weight drugs and protein pharmaceuticals. Different loading methods were taken 
into consideration and different film designs were investigated. For instance 
multilayer films had not been described yet, as well as coated films. The 
characterization of the obtained films was a crucial part of the project as well. The 
analytical information collected will help in the future when choosing the right 
medical application as well as suitable drugs for a successful loading and release 
process. The last part of this project addresses the need to automate the film 
casting process using a film applicator. Spider silk protein films could be used for 
several pharmaceutical and medical purposes, especially in situations where the 
mechanical strength of a drug eluting device is of high relevance. Benchmarking of 
this new material against standard implant polymers like PLGA and novel full 
 
27 
 
synthetic polymers will allow positioning the new material in the field.  
 
The aims of this work can be defined as: 
1. Development of a reproducible all-aqueous protein film production process 
2. Manufacturing of water-based spider silk films having superior mechanical 
properties compared to marketed films 
3. Evaluation of spider silk films as novel carrier for various pharmaceuticals
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2. Materials 
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2.1.  Reagents and Chemicals 
The reagents and chemicals used during this work are listed in the following table: 
Table 3: Reagents and chemicals 
Description Description/Purity Provider 
Acetonitrile HPLC grade VWR Chemicals, Germany 
Bromophenol blue solution Ph. Eur. Merck, Germany 
Di-potassium hydrogen 
phosphate 
 
 
≥ 98.0% Sigma-Aldrich, Germany 
Di-sodium hydrogen 
phosphate 
 
≥ 99.5% AppliChem, Germany 
Ethanol 70% v/v VWR Chemicals, Germany 
Ethacridine-lactate Ph. Eur. Fagron GmbH, Germany 
FITC-Dextran  
Average molecular 
weight: 21 kDa 
Sigma-Aldrich, Germany 
Glycerol Ph. Eur. Ceaser & Loretz, Germany 
Guanidinium thiocyanate For molecular 
biology 
AppliChem, Germany 
Hydrochlorid acid 1 M AppliChem, Germany 
Mark 12TM  - Invitrogen, USA 
Methanol HPLC grade VWR Chemicals, Germany 
Nipagin 
 
Ph. Eur. Fagron GmbH, Germany 
Paracetamol Ph. Eur. Fagron GmbH, Germany 
Phenol red Suitable for cell 
culture 
Sigma-Aldrich, Germany 
Polyethylene glycol  
 
Molecular weight 
range:  16-24 kDa 
Sigma-Aldrich, Germany 
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Potassium chloride 
 
≥ 99.5% AppliChem, Germany 
Potassium di-hydrogen 
phosphate 
≥ 98.0% Sigma-Aldrich, Germany 
2-Pyrrolidone ≥ 99.0% Sigma-Aldrich, Germany 
Sodium Azide ≥ 99.5% Sigma-Aldrich, Germany  
Sodium chloride 
 
≥ 99.9% AppliChem, Germany 
Sodium di-hydrogen 
phosphate 
≥ 99.0% AppliChem, Germany 
Sodium dodecyl sulphate ≥ 99.0% Sigma-Aldrich, Germany 
Sodium hydroxide 1 M AppliChem, Germany 
Tetracaine-HCl 
 
Ph. Eur. Fagron GmbH, Germany 
Trizma® base ≥ 99.9% Sigma-Aldrich, Germany 
 
2.2. Proteins 
The following proteins have been used in this work:  
Table 4: Proteins 
Description Description/Purity Provider 
eADF4(C16) Spray dried AMSilk, Germany 
Lysozyme from chicken egg 
white 
≥ 90.0% Sigma-Aldrich, Germany 
Albumin–fluorescein 
isothiocyanate conjugate 
- Sigma-Aldrich, Germany 
Nerve growth factor 
0.5 mg/mL, 100 mM 
acetate buffer pH 6.0 
From stock 
Erythropoietin 
0.65 mg/mL, 20 mM 
phosphate buffer pH 
7.2 
From stock 
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2.3. Buffers 
The following buffer compounds were used in this work. All buffers were 
prepared using demineralized water. 
Table 5: Buffers 
Tris/HCl buffer, 5 mM, pH 8 
Tris trisma® base  5 mM 
Hydrochlorid acid to pH 8.0 
PBS 10 mM, pH 7.4  
KH2PO4 1 mM 
Na2HPO4 10 mM 
NaCl 137 mM 
KCl 2.7 mM 
Sodium azide 0.05% w/v 
HPLC-RP Buffer  
Mobile Phase I HPW + ACN 10% + TFA 0.1% 
Mobile Phase II ACN 100% + TFA 0.1% 
SEC buffer A, pH 7.0 (NGF) 
Potassium phosphate buffer 200 mM 
KCl 450 mM 
SEC buffer B, pH 7.0 (eADF4(C16)) 
Potassium phosphate buffer 50 mM 
Sodium chloride 300 mM 
Laemmli Buffer 
Tris(hydroxymethyl)-aminomethane 250 mM 
Glycerol 23% 
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Bromophenol blue 0.1% solution 1%  
Sodium dodecyl sulphate 4% 
 
2.4. Kit used for SDS-Page 
Table 6: Kit 
 
Description Provider 
SilverXpress® 
 
Invitrogen, USA 
 
2.5. Software 
Table 7: Software 
 
Description Provider 
Origin 8G OriginLab Corporation, USA 
Opus 6.5 Bruker, USA 
Chromeleon Dionex, Germany 
Microsoft Office 2010 Microsoft, USA 
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3. Preparation and Analysis of 
Water-based SSP Films 
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3.1. Introduction 
 
This Chapter focuses on the investigation of water-based spider silk film physical- 
and chemical-characteristics. Before starting to consider any biomedical 
application for this new biomaterial, it is mandatory to understand first the film´s 
properties. Prior casting the film, the spider silk protein solution was analyzed by 
SDS-PAGE and HPLC-SEC in order to gain information on the protein eADF4(C16) 
in solution. Additionally the viscosity and the surface tension of the casting 
solution were measured to identify important properties which will become 
relevant during the manufacturing process. In this Chapter all films were cast 
manually by solvent evaporation technique. The resulting water-based 
eADF4(C16) films were characterized in terms of protein secondary structure, 
thermal stability, zeta-potential, solubility in water, mechanical properties, and 
finally, water absorption and desorption. Furthermore changes in the protein 
structure were investigated in the film matrix after a methanol post-treatment. 
3.2. Methods 
3.2.1. Preparation of the Spider Silk Casting Solution  
Spray-dried eADF4(C16) protein was dissolved in 6 M guanidinium thicynate 
GdmSNC and subsequently dialyzed against 5 mM Tris/HCl buffer, pH 8 at 4°C. 
The pH of the protein solution was determined using a pH meter MP 220 (Mettler 
Toledo, Giessen, Germany). The protein solution was centrifuged for 15 min at 
10000 rpm and filtered through a 0.45 μm cellulose acetate filter. The protein 
concentration was determined UV-photometrically using a NanoDrop 2000 
system from peqlab (Erlanger, Germany). Spider silk solution was finally diluted 
with 4°C cooled Tris buffer to 2.5% w/v.   
3.2.2. Analysis of the Protein Casting Solution 
3.2.2.1. Viscosity and surface tension of the protein casting solution 
The viscosity of the eADF4(C16) water solution was measured at 24°C using a 
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viscometer m-VROC chip A (RehoSense, Inc.). The tensiometer K100 (Krüss, 
Hamburg, Germany) was used to define the surface tension of the casting solution. 
The device was equipped with a Krüss standard plate, the velocity was set as 6 
mm/min, the immersion depth was 2 mm, and the measurements were carried 
out at 25°C as triplicate.  
3.2.2.2. SDS-PAGE of the Casting Solution 
After dialysis, eADF4(C16) solution was mixed 1:1 with Laemmli buffer. The 
Laemmli buffer consisted in Tris(hydroxymethyl)-aminomethane 250 mM, 23% 
glycerol, 4% sodium dodecyl sulphate, and 1% of a bromphenol blue 0.1% 
solution. The final concentration of the spider silk protein was 12 µg/mL. A 
thermostat Grant QBT (Grant Instruments, Cambridgeshire, UK) was used to heat 
the mixture to 95°C for 20 minutes. After equilibrating the sample at room 
temperature, the mixture was pipetted into a well of a Novex NuPAGE 12% Bis–
Tris gel (Life Technologies, Carlsbad, USA). Mark12 (Life Technologies, Carlsbad, 
USA) was used as protein standard as a reference to evaluate the size of the 
components. Gel electrophoresis was performed using a chamber (Bio-Rad 
Munich, Germany). The module was filled with a 20 fold diluted Novex NuPAGE 
MES SDS-Running buffer (Life Technologies, Carlsbad, USA). Electrophoresis was 
carried out applying 100 V for 10 min followed by 160 V for 30 min. After the 
separation step, the gel was treated following the Silver Xpress® protocol [155]. 
Finally, imaging of the gel was obtained by scanning the gel (Epson Perfection 
V370, Epson, Japan). 
3.2.2.3. Size Exclusion High Performance Liquid Chromatography of the 
Casting Solution 
The casting solution was diluted with Tris buffer to 1.5 mg/mL. This solution was 
then further diluted in order to create a calibration curve (from 96.4 µg/mL to 1.5 
mg/mL). Finally, samples were placed in the autosampler ASI-100 (Dionex Softron 
GmbH, Germering, Germany). Size exclusion high performance liquid 
chromatography was performed using a Dionex HPLC system (ASI 100, P 680, RF 
2000, Dionex Softron GmbH, Germering, Germany) equipped with a column YMC-
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Pack Diol-120 (YMC Europe GmbH, Dinslaken, Germany). The mobile phase used 
was a potassium phosphate buffer 50 mM pH 7.0 containing 300 mM sodium 
chloride. Flow rate was set to 0.5 mL/min, and 50 µL of each sample were injected. 
Protein detection was carried out using a fluorescence detector RF 2000 (Dionex 
Softron GmbH, Germering, Germany) at an excitation wavelength of 288 nm and 
an emission wavelength of 344 nm.  
3.2.3. Manual Film Casting of Spider Silk Films 
Each film was cast using 1 mL of the silk solution. The silk solution was dropped 
on a plastic foil A5 22/5B from mtv-messtechnik (Cologne, Germany, Figure 2), 
and using the pipette tip it was spread into a rectangular shape. Films (2.5x3 cm; 
3.33 mg/cm2) were cast and dried in a laminar flow cabinet at room temperature 
overnight at 45% relative humidity. The humidity was controlled placing 5 L of a 
saturated solution of potassium carbonate bihydrate [156] in the laminar flow 
cabinet. Spider silk films containing the plasticizer glycerol or 2-pyrrolidone were 
prepared dissolving 1% w/v of the plasticizer in the eADF4(C16) casting solution, 
and finally films were cast as described above. 
 
Figure 2: Plastic foil A5 22/5B from mtv-messtechnik (Cologne, Germany) used as 
substrate to cast spider silk films 
 
3.2.4. Spider Silk Film Morphology 
Photographs of eADF4(C16) films were obtained using a digital camera DSC-S75 
(Sony Corporation, Tokyo, Japan), or a digital microscope Keyence VHX-500F 
(Keyence Corporation, Osaka, Japan). Scanning electron micrographs of film 
surface were collected after the films were immobilized on Leit-Tabs (Plano 
GmbH, Wetzlar, Germany) to a sample holder. Samples were carbon sputtered 
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under vacuum and analyzed by Joel JSM-6500F field emission scanning electron 
microscope (Joel Inc., Peabody, USA). Samples were viewed at a magnification of X 
1000, X 5000, X 30000 and X 40000. SEM pictures were collected with the support 
of Christian Minke. 
3.2.5. Diffusion of Different Molecules through the Spider Silk 
Film Matrix 
The diffusion of different model molecules (paracetamol, FITC-dextrans and FITC-
BSA) through eADF4(C16) film matrices was studied via a Franz-Cell setup. The 
water jacket of each Franz Cell was connected to a water bath to maintain the 
temperature constant at 37°C. The acceptor compartment was filled with PBS 
buffer. A magnetic bar stirrer was placed in the acceptor unit. Spider silk films 
were placed between two hydrophilic polypropylene filters (pore size 0.45 µm, 
Pall Corporation, Ann Arbor, Michigan). Both film and membranes were 
previously immersed in PBS buffer to allow them to adhere closely together 
removing any possible air bubbles. Membranes and film were placed over the 
acceptor compartment in contact with the buffer. Afterwards, the donor unit was 
mounted on the top of the acceptor compartment and the two compartments were 
fixed together by a clamp. The donor compartment was additionally sealed with 
parafilm®M roll (Bemis Company, Inc., Bonn, Germany) and finally, the complete 
Franz Cell system was left to equilibrate overnight at 300 rpm. The day after, the 
donor compartment was filled with 2 mL PBS buffer containing 5 mg/mL of the 
model substance. At the defined time points of: 30, 60, 120, 180, 240, 300 and 390 
min, the concentration of the model molecule was measured in the acceptor 
compartment. Paracetamol samples were analyzed UV-photometrically using a 
Nanodrop 2000 at the wavelength of 242 nm, while FITC-dextran and FITC-BSA 
samples were measured by a fluorescence spectrophotometer Cary Eclipse Varian 
(Agilent technology, Böblingen, Germany) applying an excitation wavelength of 
490 nm and an emission of 520 nm. Film integrity was checked before and at the 
end of the experiment. Blank samples were considered studying the diffusion of 
the model substances through two polypropylene membranes 0.45 µm (Pall 
Corporation, Ann Arbor, Michigan) without spider silk films. 
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3.2.6. Protein Secondary Structure of Water-based Spider Silk 
Films  
Fourier transform infrared (FT-IR) spectra were collected using a Hyperon 
microscope from Bruker Optik (Bruker, Germany) using a 20x attenuated total 
reflectance objective (ATR). The spectra were averaged with 120 scans at the 
resolution of 4 cm-1. All measurements were performed in the range of 600 and 
4000 cm-1. In one case, four different films were considered and the 
measurements were carried out for each film in three different areas: in the 
middle, next to the border and between the middle and the border. In a second 
case, seven different areas of the same spider silk film were analyzed with this 
technique.  
3.2.7. Mechanical Properties of Spider Silk Films  
Measurements were performed using a Zwick tensile tester Z0.5 (Zwick GmbH & 
Co. KG, Ulm, Germany), equipped with a 5 N capacity load cell. The length gauge 
was 10 mm. All spider silk films were tested in a dry state. The measurements 
were carried out on different days. For these reasons, both temperature and 
relative humidity (RH) was recorded for each measurement. Films were cut into 
strips of 2x120 mm. The thickness was determined using a Mitutoyo pen 
(Mitutoyo Deutschland GmbH, Neuss, Germany). Tensile test of spider silk films 
(n=5) were carried out at 24°C and 43% RH; spider silk films containing 1% w/v 
glycerol (n=5) were measured at 25°C and 29% RH; and finally, spider silk films 
containing 1% w/v 2-pyrrolidone (n=5) were analyzed at 26°C and 41% RH. 
Spider silk films mechanical properties were compared with three standard films 
made from Nylon 66, Poly-L-lactic-acid (PLLA) and ultra-high-molecular-weight 
polyethylene (LMWPE) respectively. The mechanical properties of these films 
were measured with the method described above. Nylon measurements (n=10) 
were performed at 42% RH at 24°C; while PLLA (n=10) and LMWPE (n=5) 
measurements were performed at 40% RH at 25°C. All these standard films were 
purchased from GoodFellow (Bad Nauheim, Germany). The mechanical properties 
measuraments were carried out by Michael Bergfield from AmSilk.    
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3.2.8. Thermal Analysis of Water-based Spider Silk Films 
Thermograms of spider silk films were obtained by differential scanning 
calorimetry (DCS 204 Netzsch, Selb, Germany). Spider silk films were loaded in 
aluminum pans and a small hole was punched in the pan covers. Samples were 
heated under nitrogen flow at 10 K/min up to 110°C, then cooled to -40°C, 
followed by heating to 400°C [145].  
3.2.9. Solubility Test for Spider Silk Films 
At least three films (3 x 2.5 cm) were weighed and placed in a 6-well plate. Each 
film was covered with 2 mL of highly purified water. The well plate was positioned 
on a shaking plate at 2 rpm at room temperature. After 1 h, 24 h, three days and 
six days, the water was removed and analysed by spectrophotometer Agilent 8453 
(Boeblingen, Germany). Protein concentration in solution was determined UV-
photometrically. The amount of the dissolved spider silk was compared with the 
initial mass of the film obtaining the percentage of the loss in mass of the film in 
water. The same experiment was performed in 0.01 M PBS buffer pH 7.4 at 37°C. 
3.2.10. Methanol Post-treatment of Spider Silk Films  
A MeOH post-treatment was performed incubating water-based spider silk films 
in 5 mL of MeOH (HPLC quality) for 30 min, 1 h, 24 h and 72 h. Six films were 
treated for every time conditions. Three of them were analyzed by FT-IR (Method 
3.2.6) followed by DSC measurements (Method 3.2.8), and three of them were 
used for studying their water solubility (Method 3.2.9). 
3.2.11. Water Absorption and Desorption of Spider Silk Films  
Measurements were performed according to the method previously published 
[157] using a Moisture Analyzer IGASorp (Hiden Analytical, Germany) with a 
microbalance resolution of 0.1 µg and a minimal humidity step change of 0.2%. 
Briefly, eADF4(C16) films were incubated at constant temperature of 25°C and a 
nitrogen flow rate of 200 mL min-1, while the relative humidity was increased 
from 0 to 90%. Three absorption and desorption cycles were performed assuming 
an absorption of zero at 0% relative humidity. 
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3.2.12. Zeta-potential Measurements of Spider Silk Films 
The zeta-potential measurements were performed using a SurPass electrokinetic 
analyser, having an integrated titration unit and equipped with the adjustable gap 
cell (Anton Paar GmbH, Graz, Austria). These experiments were carried out by 
Thomas Luxbacher from Anton Paar.  
 
3.3. Results and Discussion   
3.3.1. Water-based Casting Solution 
The primary structure of the recombinant spider silk protein eADF4(C16) is rich 
in alanin, glycin and prolin [146]. The high content of these hydrophobic amino 
acids leads to low water solubility of the protein [94]. In order to prepare a water-
based casting solution (Method 3.2.1) the protein needs to be dissolved at first in a 
solvent containing a high concentration of guanidinium thiocyanate, a protein 
unfolding agent. After that, a slow dialysis needs to take place to remove the 
unfolding agent. For the purpose of this project, a buffer of 5 mM Tris/HCl was 
used as dialysis buffer. It was chosen due to its pH range and its inertia towards 
the spider silk protein, since for instance high concentration of phosphate ions can 
trigger the aggregation of eADF4(C16) [65]. The molar concentration of Tris in the 
buffer was defined as low as possible, with the intention to avoid the formation of 
salt crystals in the film matrix after the evaporation of the solvent during film 
preparation. After dialysis, a transparent, colorless, spider silk protein buffer 
solution having a final concentration of 30 mg/mL eADF4(C16) was obtained. It 
has been reported by Huemmerich et al., that the recombinant protein 
eADF4(C16) is characterized by random coiled structures when dissolved in 
aqueous solution [152]. In this work, the casting solution was analyzed by SDS-
PAGE (Method 3.2.2.2) and HPLC-SEC (Method 3.2.2.3). The SEC chromatogram 
(Figure 3) showed the presence of aggregates (peak 11.5 min and peak 12.7 min) 
followed by the main eADF4(C16) peak (at 14.7 min). The protein main peak is 
characterized by a large tailing (from 14.7 to 29 min), suggesting the presence of 
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different eADF4(C16) fragments, which was also confirmed by SDS gel analysis 
(Figure 4). Here, the main protein signal was present at around 67 kDa, followed 
by numerous smaller molecules bands of 66-37 kDa.  
 
 
Figure 3: Example of HPLC-SEC chromatogram of the recombinant spider silk protein 
eADF4(C16) in the casting solution before film casting. 
 
 
 
Figure 4: SDS-Page gel of the recombinant spider silk protein eADF4(C16) in the casting 
solution before film casting. 
 
The physical characteristics of the spider silk casting solution will play an 
important role in the industrialization of the manufacturing process. In Table 8, the 
viscosity and the surface tension of the casting solution are listed. 
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Table 8: Physical properties of the spider silk casting solution 
 
3.3.2. Morphology and Surface of SSP Water-based Films 
The casting solution was always processed into films the same day after 
completing the dialysis process. By casting (Method 3.2.1) spider silk films from 
aqueous solvents, transparent films having a homogeneous morphology and a 
smooth surface were obtained.  
The average thickness of the films was about 29 ± 4 µm. Films prepared with this 
method were easy to handle, and the process was found to be reproducible.  
 
Figure 5: Photograph of eADF4(C16) films cast by solvent evaporation technique, film 
dimensions: 2.5 x 3 x 0.03 cm. Bar = 1 cm 
 
The film surface was analyzed using a digital microscope (Method 3.2.4). Overall, 
the surface was observed to be smooth, compact and homogeneous. Although, it is 
possible to observe different brighter and darker spots, those could refer to the 
presence of pores and/or protuberances. A closer analysis of the surface by SEM 
(Figure 7) highlights the absence of pores and the presence of minor extrusions, 
caused from the spider silk protein aggregation process. The high resolution of the 
Protein casting solution 
Composition 
Viscosity 
(mPa-s) 
Surface tension 
(mN/m) 
eADF4(C16) 25 mg/mL 
Tris/HCl buffer 5 mM pH 8 
2.33 ± 0.75 48.14 ± 0.04 
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micrographs C and D reveal the presence of microglobular structures which 
compose the film matrix network. Those structures have been described 
previously by Yucel et al. as the final stage of silk self-aggregation [103]. 
 
Figure 6: Images of the surface of spider silk films obtained using a digital microscope 
(Method 3.2.4). A: magnification 100x, bar = 100 µm; B: magnification 200x, bar = 100 µm 
 
 
Figure 7: Scanning electron micrographs of water-based spider silk films cast by solvent 
evaporation technique. A: Surface of a spider silk film, magnification of 1000x, bar = 10 
µm; B: Surface of a spider silk film, magnification of 5000x, bar = 1 µm; C: Cross section of 
a spider silk film, magnification of 30000x, bar = 100 nm; D: Surface of a spider silk film, 
magnification of 40000x, bar = 100 nm. 
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To further examine spider silk film, a diffusion test via Franz Cells was performed 
(Method 3.2.5). The scope of the experiment was to evaluate the diffusion of 
molecules having different molecular weights through the spider silk matrix. 
Figure 8 shows the results obtained. Since the calculated isoelectric point of 
eADF4(C16) is 3.48 [67], spider silk films are assumed to be negatively charged in 
the experiment conditions (pH 7.4). Paracetamol, a small and neutrally charged 
molecule was able to diffuse through the film matrix. On the contrary, larger 
neutrally charged molecules like dextran 4, 10, and 20 kDa, did not pass through 
the film matrix to reach the acceptor compartment during the time considered. 
The control showed that when the spider silk was not included between the two 
polyethylene membranes, dextran molecules diffused to the acceptor 
compartment.  
In the case of BSA, a globular protein negatively charged at pH 7.4 with a size of 
66.5 kDa, the molecule was not able to pass through the film to the acceptor 
compartment during the time considered. Since both film and protein (BSA) are 
negatively charged, the diffusion of the large molecule was additionally challenged 
by repulsive forces. On the other hand, BSA was able to reach the acceptor donor 
in the control during the time considered.  
In conclusion, the film surface resulted to be tight and compact; it appears that the 
film surface can act as a functional mechanical barrier for large molecules since it 
prevents their migration from the donor to the acceptor compartment.  
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Figure 8: Concentration of different molecules (A: paracetamol, B: Dextran 4 kDa, C: 10 
kDa, D: 20 kDa and E: BSA) measured in the acceptor compartment of the Franz Cells. 
Displayed by the square points in the graphs is the average concentration measured in the 
three Franz Cells having between the donor and acceptor compartment one spider silk 
film placed between two polypropylene membranes. Displayed by circle points is the 
average concentration measured in the Franz Cells used as controls, where no spider silk 
film was placed between the two membranes. 
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3.3.3. Protein Secondary Structure 
Spider silk films after casting were analyzed by FT-IR spectroscopy.  The analysis 
of the second derivate of the amide I band showed that water-based eADF4(C16) 
films were characterized by a very homogenous protein structure, with high β-
sheet content (peaks at: 1625 cm-1 and 1690 cm-1), as shown in Figure 9. This is 
true in both cases when the measurements were performed in different film areas, 
as well as in different films analyzed. The content of β-sheet structures determines 
the stability of silk films and their mechanical properties. eADF4(C16) is 
characterized by its hydrophobic nature and it is therefore insoluble in water. For 
this reason, in the past years, spider silk films have been generally cast from 
hexafluoro-2-propanol [127, 147]. Those films needed to be additionally 
processed by treating them with phosphate ions or alcohol [146, 152] in order to 
increase their β-sheet content. In agreement with the literature [48], water-based 
films usually do not contain a large amount of β-sheet protein, they mainly consist 
of random coil structures, and are therefore soluble in water. However, the 
preparation procedure described in this chapter results in a high content of β-
sheet protein secondary structures. This is probably caused by the drying step of 
the casting solution. During overnight, the eADF4(C16) proteins have enough time 
to fold in ordinate ß-sheet structures. Moreover, the manufacturing process used 
in this study did not involve the use of any organic solvent and did not require any 
additional post-treatment. This opens the possibility to load therapeutic proteins 
on spider silk films, without damaging this sensitive class of drugs.  
 
Figure 9: A: secondary derivative FT-IR spectra of water-based spider silk films (n=4, 
every spectra is the average of three different measurements of the same film). B: 
secondary derivative FT-IR spectra of one single water-based spider silk film, where 
seven different areas where analyzed. 
A B 
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3.3.4. Thermal Analysis 
DSC scans showed the typical bimodal melting/thermal decomposition of the 
spider silk films [145] with a shoulder at 259 ± 3.5°C and an endothermic peak at 
335.8 ± 1.4°C (Figure 10). The glass transition temperature (Tg) was measured at 
214.2 ± 1.5°C, showing excellent thermal stability of the films up to 200°C, which 
could be relevant for several future technical applications as it allows steam 
sterilization of eADF4(C16) films. In a recent work, spider silk particles have been 
successfully sterilized by moist heat. Lucke et al. showed that the combination of 
high temperature, humidity and pressure did not affect the secondary structure of 
eADF4(C16) particles [158]. 
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Figure 10: DSC thermograms of water-based spider silk films (n=3); Tg represents the 
glass transition temperature. 
 
 
3.3.5. Water Solubility 
After preparation, it was important to determine the amount of spider silk protein 
within the films that may have not been converted into its water-insoluble form. 
Films were incubated in highly purified water at room temperature and in PBS 
buffer 10 mM at 37°C. It was observed that approximately 5-6% w/w of spider 
silk protein could be detected in the supernatant (Table 9), and that the majority of 
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spider silk protein dissolved during the first hour.  
 
Table 9: Cumulative amount of eADF4(C16) protein solubilised from  water-based spider 
silk films (n=3). 
SOLUBILITY    
% (w/w) 
 1 h 1 day 3 days 6 days 
HPW (RT°C) 4.67 ± 0.01 5.45 ±  0.06 5.63 ± 0.06 5.81 ± 0.05 
PBS (37°C) 4.99 ± 0.01 6.02 ± 0.14 6.23 ± 0.15 6.43 ± 0.17 
 
After 1 h incubation in highly purified water, three spider silk films were analyzed 
by DSC (Method 3.2.8) and FT-IR (Method 3.2.6). The thermograms presented in 
Figure 11 were characterized by an increased Tg: from 214°C of untreated films to 
237°C of the films incubated in water. This change can be explained by an increase 
of β-sheet content in the film matrix. This hypothesis was confirmed by the 
analysis of the protein secondary structure performed using the FT-IR 
microscope. In fact, the intensity of the main β-sheet peak at 1625 cm-1 increased 
notably after incubation in water (Figure 12).   
 
Figure 11: Thermograms of water-based spider silk films after incubated for 1 h in highly 
purified water, n = 3. 
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Figure 12: Second derivate of the FT-IR spectra of water-based spider silk films, before 
and after have incubation of the films in highly purified water for 1 h. Every spectra 
represents the average of nine different measurements of three different films (three 
measurements for each film). 
 
3.3.6. Methanol Post-treatment 
The treatment of silk films with methanol after casting is a common technique, as 
it is normally used to increase the content of crystal structures in the film matrix 
in order to achieve water insolubility [143, 146, 147, 152]. To investigate the 
impact of this particular post-treatment on water-based spider silk films, films 
were incubated in methanol for different time frames: 30 min, 1 h, 1 day and 3 
days (Method 3.2.10). Afterwards, their thermal stability (Method 3.2.8) and 
protein secondary structure (Method 3.2.6) was analyzed. The glass transition 
temperature was found to be directly correlated with the time of treatment: the 
longer the incubation in methanol, the higher was the Tg measured (Table 10). This 
indicates that the content of β-sheet structures increased. In accordance with the 
DSC data, the FT-IR spectra showed that the β-sheet peak intensity (1625 and 
1690 cm-1) increased notably after 1 and 3 days treatment; while only smaller 
differences were measured for the films treated for 30 min and 1 h.  
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Table 10: Glass transition temperatures (Tg) measured from the thermograms of water-
based spider silk films treated with methanol for different time frames, n = 3 for each 
condition. 
 
Time 
MeOH 
Post-treatment 
Tg (°C) 
none 214.2 ± 1.5 
30 min 230.6 ± 0.8 
1 h 233.3 ± 2.3 
24 h 239.8 ± 1.4 
3 days 242.2 ± 2.6 
 
 
Figure 13: Second derivate FT-IR spectra of water-based spider silk films, before and after 
incubation in methanol water for: 30 min, 1 h, 24 h and 72 h. Every spectra is the average 
of nine different measurements of three different films (three measurements for each 
film). 
 
Furthermore, the water solubility of the treated films was tested (Table 11). It was 
found that the methanol treatment did slightly decrease the water solubility of 
spider silk films. After 6 days of measurements, the untreated films lost around 
5.8% of their initial mass, while films treated with methanol lost between 5.7 and 
4.4%. Although, only after 1 day of post-treatment it was possible to notice a 
distinguished difference between untreated and treated films.  
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Table 11: Water solubility of water-based spider silk films post-treated with methanol for 
different time frames, n = 3 for each condition 
 
 Loss in Mass % w/w measured after: 
Time of 
treatment with 
MeOH 
1 h 1 day 3 days 6 days 
none 4.67 ± 0.01 5.45 ± 0.06 5.63 ± 0.06 5.81 ± 0.05 
30 min 4.55 ± 0.03 5.36 ± 0.04 5.56 ± 0.04 5.72 ± 0.06 
1 h 4.32 ± 0.12 5.25 ± 0.06 5.48 ± 0.03 5.62 ± 0.04 
1 day 3.36 ± 0.07 4.19 ± 0.07 4.47 ± 0.09 4.65 ± 0.07 
3 days 3.12 ± 0.05 3.94 ± 0.04 4.23 ± 0.02 4.42 ± 0.01 
 
In conclusion the methanol treatment was not employed for further studies in this 
thesis, as it did only slightly increase the water insolubility of films. Furthermore, 
the methanol treatment represents s an additional process, which requires rather 
long incubation times and involves the use of an organic and toxic solvent.  
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3.3.7. Water Absorption and Desorption 
In order to analyze potential differences in hydration behavior of the films, water 
absorption and desorption isotherms were collected by IGASorp (Figure 14).  
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Figure 14: Water absorption and desorption profiles of water-based spider silk films. 
Each point represents three measurements of the same film.  
 
As shown in Figure 14, after 3 cycles of water absorption and desorption, the 
hydration behavior of the film did not change. Spider silk films can adsorb water 
up to 28% of their weight. No substantial hysteresis was observed, suggesting a 
completely reversible hydration state of these protein films.  
 
3.3.8. Zeta-potential 
Electrostatic interactions have been shown to play a major role in drug loading 
onto spider silk particles [65] and spider silk films [143]. Therefore, water-based 
spider silk films were further characterized regarding their surface charge using 
the SurPass instrument (Figure 15). The experiment was carried out by Dr. 
Thomas Luxbacher from Anton Paar.  
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Figure 15: Zeta-potential measurements of water-based spider silk films (n=3). 
 
The isoelectric point of eADF4(C16) proteins in films was measured at around 5, 
meaning that spider silk films were positively charged at a pH below 5 and 
negatively charged at a pH above 5. In conclusion, water-based spider silk films 
are negatively charged at physiological pH.  
3.3.9. Mechanical Properties 
With regard to the mechanical properties, spider silks are undoubtedly 
remarkable polymers [51, 77]. However, films prepared from aqueous solution 
showed a very high elastic modulus, although only a low elongation (Table 12). It 
appeared that spider silk films were not as elastic as natural spider silk [77]. This 
is due to the fact that the recombinant protein eADF4(C16) is based on the amino 
acid sequence of the natural spider silk protein ADF4, which along with the 
protein ADF3 composes the major ampullate silk produced by the spider A. 
diadematus [78]. This is a kind of silk characterized by high strength, while other 
silks, e.g. flagelliform silks, are known for their elastic properties [78]. According 
to that, water-based eADF4(C16) films exhibit impressive tensile strength, above 
5000 MPa. This quality could be fundamental for different applications where 
stiffness plays an important role in designing products which have a maximum 
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deflection requirement. To assess the spider silk films´ tensile properties, those 
were compared with the mechanical properties of three standard materials in 
Table 12. Overall, spider silk films showed similar mechanical properties like 
poly(l-lactic acid) films. In general, eADF4(C16) films cast from water were stiffer 
than Nylon 66, poly-(l-lactic-acid) and ultra-high-molecular-weight polyethylene 
films. On the other hand, water-based spider silk films were very brittle compared 
to these standard films.  In order to increase the film elasticity, plasticizers were 
included in the film casting solution. The addition of glycerol or 2-pyrrolidone as 
plasticizers in the film matrix resulted in a tremendous increase in elongation (60 
times higher), and in a loss in stiffness (12 times lower) (Table 12). In conclusion, 
the incorporation of small hydrophilic plasticizers can affect the mechanical 
properties of water-based spider silk films increasing their elasticity but reducing 
their stiffness. These measurements were carried out by Michael Bergfield from 
AmSilk. 
 
Table 12: Tensile test of different spider silk films and comparison with three standard 
films made from Nylon 66, poly(l-lactic acid) (PLLA) and ultra-high-molecular-weight 
polyethylene (UHMWPE) respectively. h: thickness Et: elastic modulus; σM: tensile 
strength maximal; εM: elongation at maximal strength (% over the initial length). 
 
FILM h (μm) Et (MPa) σM (MPa) εM (%) 
eADF4(C16)  29 ± 4 5500 ± 530 81.2 ± 34.8 1.8 ± 0.83 
eADF4(C16)  + glycerol 31 ± 5 458 ± 164 20.6 ± 1.97 110 ± 21 
eADF4(C16)  + 2-pyrrolidone 35 ± 6  274 ± 99.1 36.9 ± 4.35 130 ± 18 
Nylon 66  25 1170 ± 62.7 68.6 ± 6.9 470 ± 86 
PLLA  50 3210 ± 84 35.9 ± 0.2 1.3 ± 0.05 
UHMWPE 75 752 ± 52 23.6 ± 0.01 350 ± 55 
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3.4. Conclusion 
 
In this study, spider silk films cast from aqueous solution were prepared without 
the use of any organic solvent. The film surface was smooth, compact and 
homogeneous. Only small molecules were able to diffuse through the film matrix. 
Water-based spider silk films were characterized by a high content of β-sheet 
protein structures, which led to water insolubility and to a high elastic modulus. 
The elongation of the films can be increased by adding small hydrophilic 
plasticizers in the casting formulation. Methanol post-treatment slightly increased 
water insolubility, and therefore it was concluded that such treatment was not 
necessary. Thermal analysis showed that spider silk films showed excellent 
thermal stability up to 200°C. The films were negatively charged at physiological 
conditions. In conclusion, the protein secondary structure was responsible for the 
film properties, therefore its analysis is essential to predict and understand the 
film’s behavior. An useful analytical tool to evidence the secondary structure of the 
protein eADF4(C16) in the film matrix were the combination of DSC and FT-IR.   
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4. SSP Films as Drug Delivery 
Matrices 
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4.1. Introduction 
 
The aim of this Chapter is to investigate the potential of spider silk films as drug 
delivery matrices. Films were loaded with a variety of molecules (phenol red, 
paracetamol, ethacridine-lactate, nipagin, tetracaine hydrochloride, lysozyme, 
dextran, and albumin–fluorescein isothiocyanate conjugate) exploring two 
different loading techniques: remote loading and direct loading. Furthermore, 
different film designs were prepared, such as: monolayer, coated monolayer, 
multilayer (sandwich), and coated multilayer. This investigation focused also on 
possible improvements in the film’s mechanical properties using glycerol and 2-
pyrrolidone as plasticizers in the film matrix. Additionally, this Chapter reports on 
a new method to prepare spider silk multilayer films. Here the model protein BSA 
was embedded in a sandwich format. It was then studied how the presence of a 
plasticizer in the film matrix affects the release of the model protein BSA. 
Furthermore, various water-based eADF4(C16) films were coated with a 
concentrated spider silk solution and the release of the model protein BSA from 
these new systems was studied. Finally, the biodegradation in vitro of spider silk 
films containing 2-pyrrolidone was also considered. The main focus of this work 
was to obtain a drug delivery matrix characterized by biocompatibility, water 
insolubility and good mechanical properties. Moreover the preparation process 
should be compatible with protein encapsulation and the obtained matrix should 
be able to release a model protein for a prolonged time. 
 
4.2. Methods 
4.2.1. Remote loading of LMW Drugs and Lysozyme  
Low molecular weight drugs phenol red, paracetamol, ethacridine-lactate, nipagin, 
and tetracaine hydrochloride were dissolved at a concentration of 0.5 mg/mL in 
highly purified water (HPW), Tris 5 mM pH 7, and formate buffer 5 mM, pH 3, 
respectively. After dissolving the drugs, all solutions were filtered through a     
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0.45 µm cellulose acetate filter to remove particles. Calibration curves for each 
drug solution were prepared using a NanoDrop 2000 (peqlab, Erlanger, Germany). 
For the remote loading process, the previously cast spider silk films were cut into 
4 pieces, weighed and placed into 24-well plates. At least four film samples were 
incubated with 1 mL of each drug solution for 30 min at gentle agitation with 2 
rpm at room temperature. After removing the films, the quantities of the loaded 
drugs were calculated indirectly by measuring the remaining loading solutions 
photometrically by NanoDrop. Finally, the loading efficiency (LE) for each 
experimental condition was calculated as follows: 
 
 
[65] 
 
For the remote loading of a model protein, the loading solution was prepared 
dissolving 1% w/v lysozyme in HPW. Three different films were weighed. 
Afterwards, films were incubated in a 6-well plate with 5 mL of the loading 
solution at room temperature at 2 rpm. After 30 min, films were removed and the 
loading solution was analysed UV-photometrically at 280 nm. Spectra were 
recorded using a spectrophotometer (Agilent Technologies 8453, Oberhaching, 
Germany). A calibration curve was prepared using a lysozyme solution. The 
loading and loading efficiency were calculated as described above. 
4.2.2. Direct Loading and Release of Paracetamol, Dextran, and 
BSA 
2.5% SSP1 protein solution was prepared as described in 3.2.1. Before casting the 
films, tetracaine hydrochloride and paracetamol as model drugs were added and 
dissolved directly in the spider silk protein solution, respectively. Films were 
casted as described above. The resulting films contained each 2.5 mg of drug  
(0.33 mg/cm2). Three film samples containing paracetamol were incubated in 0.01 
M PBS buffer pH 7.4 at 37°C, 5 rpm. 0.05% w/v sodium azide was added to the 
LE (w/w %) = ∙100 
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phosphate buffer as preservative. At predetermined time points, the buffer was 
removed and replaced with fresh medium. The release buffer was analyzed by 
NanoDrop 2000 (peqlab, Erlangen, Germany) at 242 nm. The released 
paracetamol was quantified using a calibration curve. 
A 20 mg/mL of FITC-BSA, or FITC-dextran (FD), solution in 0.01 M PBS buffer pH 
7.4 was directly mixed with the spider silk solution. Films were cast as described 
above. Every film contained 25 mg of eADF4(C16) and 1.3 mg (173 µg/cm2) of 
FITC-BSA or FD. Films containing the model drugs were incubated in 0.01 M PBS 
buffer pH 7.4 at 37°C, 5 rpm. Again, 0.05% w/v sodium azide was added to the 
phosphate buffer as preservative. At predetermined time points the buffer was 
removed and replaced with fresh medium. The release buffer was analyzed by a 
fluorescence spectrophotometer Cary Eclipse Varian (Agilent technology, 
Böblingen, Germany) applying an excitation wavelength of 490 nm and an 
emission of 520 nm. FD and FITC-BSA releases were quantified using a calibration 
curve. The drug, which was not released, was quantified by dissolving the film 
matrix in a 6 M GudmSCN solution. This solution was subsequently analyzed using 
the fluorescence spectrophotometer. The quantity of the non-released drug was 
determined again using a calibration curve. The sum of the non-released 
substance and the released amount of substance was calculated as 100%.  
4.2.3. Preparation of Multilayer Films, Loading and Release of 
BSA  
Films containing the model protein FITC-BSA were prepared by adding 1% w/v of 
glycerol directly in the casting solution (3.2.1.) and mixing it for 3 min. Afterwards, 
a 20 mg/mL FITC-BSA solution in 0.01 M PBS buffer pH 7.4 was directly mixed 
with the spider silk solution. Films were cast as described above. Every film 
contained 25 mg of eADF4(C16) and 1.3 mg of FITC-BSA. Typically, one film, 
containing the model protein and the plasticizer, was positioned between two 
spider silk films which did not contain any plasticizer (3.2.3) and using a hydraulic 
press 5T (Maassen GmbH, Reutlingen, Germany) films were pressed together 
applying 9.8 kN for 5 min, creating three-layers films where only the middle layer 
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contained the model protein. The release of FITC-BSA was investigated as 
described in 4.3.3.  
4.2.4. Spider Silk Coating of Film Matrices  
Monolayer films containing only the model protein FITC-BSA, monolayer films 
containing FITC-BSA and glycerol, and finally, the 3-layers films (containing 1% 
w/v glycerol and the model protein in the middle layer) were coated by dipping 
them in a 5% w/v eADF4(C16) solution. After the films were completely 
immersed in the silk solution they were placed on a plastic foil A5 22/5B from 
mtv-messtechnik (Koeln, Germany) using forceps. The contact with the forceps 
did not damage the coating formation process because once the films were 
positioned on the card, the liquid coating rearranged itself homogenously on the 
film surface. The coated films were left drying overnight at RT in the dark. The 5% 
w/v spider silk solution was prepared by a second dialysis of the previously 
protein solution obtained by the method described in 2.2.1 against 5 mM Tris/HCl 
buffer, pH 8 at 4°C, containing 10% w/v of PEG 20 kDa. The release of FITC-BSA, 
from all these different systems, was investigated as described in 2.2.9. At least 
three film samples for each condition were used for this study. 
 
 
 
4.2.5. Biodegradation of Spider Silk Films 
The biodegradability of water-based spider silk films containing 2-pyrrolidone 
(2.2.1.) was evaluated adapting the method described in [65] and in [143]. Briefly, 
Figure 16: All-aqueous coating process using a highly concentrated spider silk solution of 
multi- or mono- layers made of the same spider silk protein eADF4(C16). 
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eight films were weighted using a microbalance. Four films were incubated at 
37°C, 2 rpm, each in 2 mL PBS 10 mM pH 7.4 containing 0.8 µg of elastase and 12.5 
µg of trypsin. Meanwhile, a control group, composed by four other identical films, 
was incubated at the same condition in PBS buffer without enzymes. After defined 
time points, the incubation media were removed and films were washed twice, 
each time with 5 mL of highly purified water. Films were left to dry overnight at 
room temperature. After that, films were weighed on a microbalance and a new 
incubation step was started using fresh enzymes or buffer solution respectively. 
After ten days of this set up, the experiment continued with three films for each 
group, and this time the enzymes’ concentration was increased five times (4 µg 
elastase and 62.5 µg trypsin). The test was carried out in this new condition for 
another 6 days monitoring the film masses. After that, SEM film surface analysis 
was conducted. Scanning electron micrographs were collected after the films were 
immobilized on Leit-Tabs (Plano GmbH, Wetzlar, Germany) to a sample holder. 
Samples were carbon sputtered under vacuum and analyzed by Joel JSM-6500F 
field emission scanning electron microscope (Joel Inc., Peabody, USA). 
 
4.3. Results and Discussion 
 
4.3.1. Remote Loading 
As described in paragraph 3.2.12 (page 40), the isoelectric point of spider silk 
films is around 5. Consequently, due to electrostatic interactions, molecules with 
positive charge are attracted to the negatively charged spider silk protein matrix 
at a higher pH value than 5, while molecules with a negative charge can diffuse 
into the positively charged spider silk protein matrix at pH values below 5. For the 
remote loading strategy, five low molecular weight drugs were chosen according 
to their predominant charge at different pH values (Table 13). The influence of pH 
was investigated by performing experiments using different solutions: formate 
buffer 5 mM pH 3, Tris buffer 5 mM pH 7, and in highly purified water (HPW).  
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Table 13: Predominant net-charge of the small molecules selected at different pH 
conditions. 
  
 
pH 7 pH 3 HPW 
Paracetamol neutral neutral neutral 
Ethacridine-lactate + + + 
Nipagin neutral neutral neutral 
Phenol-red - - - 
Tetracain-HCl + + + 
 
 
Table 14: Remote loading of different small molecular weight drugs and the model 
protein lysozyme. The loading efficiency (LE) was determined at different pH and 
different ionic strength. HPW represents highly purified water. 
 
 
pH 7 pH 3 HPW 
LE (%) LE (%) LE (%) 
LMW drugs  
Tetracaine HCl 24.3 ± 7.7 0.0 ± 0.0 35.1 ± 8.3 
Ethacridine lact. 45.8 ±2.7 16.5 ± 5.4 54.2 ± 3.2 
Paracetamol 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Nipagin 0.0 ± 0.0 5.3 ± 2.3 9.6 ± 4.3 
Phenol red 7.2 ± 2.0 17.2 ± 5.0 2.8 ±  1.3 
Model Protein    
Lysozyme -- -- 22.8 ± 0.7 
 
For all the drugs investigated in this study, higher loading efficiencies were 
observed in HPW (Table 14). In this condition, the interactions between the film 
matrix and drugs may be maximized due the low ionic strength. Tetracaine 
hydrochloride and ethacridine monohydrate lactate were positively charged at all 
pH values tested. As expected, at pH 3 the loading was found to be considerably 
lower compared to the loading of the eADF4(C16) matrix at pH 7 and in HPW. 
That can be explained by the fact that at pH 3, eADF4(C16) films are positively 
charged and the remote loading of positively charged drugs is therefore severely 
limited. As expected, no loading of the spider silk films was measured for 
paracetamol. Since paracetamol is a neutral molecule, no loading was possible due 
 
63 
 
to the lack of electrostatic interactions. In contrast, some loading was observed for 
nipagin at pH 3 and in HPW. Nipagin is a neutral molecule such as paracetamol, 
but in these circumstances the remote loading probably occurred due lipophilic 
interactions. Nipagin is characterized by a logP of 1.86, while paracetamol has a 
logP of 0.38. Therefore it is conceivable to assume that the loading of nipagin took 
place due to its lipophilic affinity with the hydrophobic protein eADF4(C16). In 
fact, the mean hydrophaticity of this spider silk protein has been calculated -0.464, 
describing its poor water solubility [94]. A similar aspect was observed in case of 
remote loading of phenol red. Phenol red exhibits a negative charge at all 
conditions investigated in this study. Reasonably, the highest loading was 
measured at pH 3. Nevertheless, surprisingly some loading was also observed at 
pH 7 and in HPW. These measurements can be explained considering that phenol 
red is characterized by a logP about 3. This leads to the conclusion that not only 
electrostatic interactions, but also hydrophobic interactions seem to play an 
important role in the remote loading of spider silk films. In a similar experiment 
conducted on eADF4(C16) particles, the same drugs that we selected were 
dissolved in water and particles were incubated in these loading solutions [65]. 
Lammel et al. measured an encapsulation efficiency of about 98.2% for 
ethacridine, 53% for tetracaine, 0.2% for paracetamol, 17.3% for nipagin, and 0% 
for phenol red. These results are in accordance with the data presented here. The 
higher encapsulation efficiency of particles, in comparison with the film loading 
efficiency, can be explained by the larger surface area displayed by particles. In a 
further step, remote loading of the model protein lysozyme was considered. 
Lysozyme has an isoelectric point of 11.35, is positively charged at physiological 
pH and should be able to interact with the negative charged eADF4(C16) film 
matrix. In fact, the remote loading of eADF4(C16) films with lysozyme performed 
in HPW, demonstrated that it is possible to load high molecular weight molecules 
by remote loading by exploiting the electrostatic interactions between spider silk 
matrix and protein (Table 14).  
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4.3.2. Direct Loading 
In the past, different molecules have been loaded on spider silk particles and 
spider silk films by remote loading [65, 67, 143]. In these studies, eADF4(C16) 
particles and films were incubated in a drug solution and the loading was mainly 
driven by electrostatic interactions. An alternative way for loading drugs is direct 
loading, which means that the water soluble drug is directly dissolved in the 
casting silk solution or, alternatively, the spider silk solution is mixed with a 
second solution containing the dissolved drug, and films are cast. The advantage of 
this method is the one-step process and the known amount of the drug directly 
incorporated, which leads to theoretical 100% of drug loading.  
To investigate the potential of this manufacturing technique, both paracetamol 
and tetracaine HCl were chosen as small molecular weight drugs, FITC-dextran 
(20 kDa) as a middle molecular weight model and finally, lysozyme (14.3 kDa) and 
FITC-BSA (66.5 kDa) were chosen as model proteins. The direct loading of 
paracetamol was successfully performed by dissolving the drug directly in the 
2.5% eADF4(C16) casting solution.  
The resulting films showed a smooth, transparent, colorless surface that 
resembled the non-loaded films. On the contrary, when tetracaine hydrochloride 
was added to the spider silk protein solution, the protein solution turned into a 
milky non-transparent solution, which resulted in inhomogeneous drug 
distribution and an irregular film surface as shown in Figure 17. Paracetamol had 
a neutral charge at pH 8 (pH of the spider silk solution), while tetracaine 
hydrochloride was positively charged, which consequently resulted in a different 
spider silk protein-drug interaction.  
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Figure 17: Image obtained with a digital microscope showing the surface of water-based 
spider silk films direct loaded with paracetamol (A1 and A2) and direct loaded with 
tetracaine hydrochloride (B1 and B2). A1 bar = 250 µm; A2 bar = 50 µm; B1 bar = 250 
µm; B2 bar = 50 µm. 
 
Similarly, no direct loading was possible in the case of lysozyme. When lysozyme 
was added to the casting solution of spider silk, protein aggregation was observed 
and no films could be cast using this mixture. Strong electrostatic interactions 
between eADF4(C16) and the direct loaded drug have a negative effect on the 
casting solution. On the other hand, direct loading of FITC-dextran, a non-charged 
polymer of 20 kDa, was achieved successfully. Similarly, direct loading was 
successfully performed by adding a solution of FITC-BSA to the casting solution. 
According with the product information of Sigma-Aldrich, BSA has a molecular 
weight of 66.43 kDa and an isoelectric point (PI) of 4.9, close to the one found for 
the spider silk protein in the film matrix (Figure 4). The two different proteins 
share the same charge at different pH values, and so, electrostatic attraction 
between them is highly unlikely. Interestingly, in a recent study it was shown that 
FITC-BSA is not able to permeate into eADF4(C16) spider silk particles [67]. So, 
while the remote loading of proteins, sharing the same charge as the spider silk 
protein (at the process pH), was impeded for a lack of electrostatic interactions, 
direct loading of these biomolecules was also difficult due to technical reasons for 
spider silk particles [65, 67]. On the contrary, direct loading of proteins was 
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possible for films. Neutral molecules (paracetamol, dextran) and molecules 
sharing the same charge (BSA) did not disturb the eADF4(C16) structure in buffer 
solution, therefore no aggregation was observed and direct loading was effectively 
accomplished. In summary, direct loading is a method applicable to those drugs 
that do not strongly interact with the spider silk protein in solution. On the 
contrary, remote loading is ideally recommended for loading of those drugs 
having a strong opposite charge and a high logP.  
4.3.3. Release from Direct Loaded Spider Silk Films 
Water-based spider silk films were direct loaded with various molecules: 
paracetamol, FITC-dextran, and FITC-BSA.  Following, the in vitro release from 
these systems has been investigated. The results of the studies on monolayer films 
showed that the release depended on the molecular weight of the drugs. On the 
one hand, spider silk films completely released paracetamol and FITC-dextran in a 
short time period (Figure 18).  
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Figure 18: Release of paracetamol (n=3), FITC-dextran (n=3) and FITC-BSA (n=4) from 
water-based eADF4(C16) films (monolayers).  
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On the other hand, the release of FITC-BSA, which is six times larger than that of 
dextran, was observed to be slower. This is in agreement with a previous 
observation in the literature [159], where a molecular weight cut-off of 27 kDa 
was reported for spider silk microcapsules. Additionally, there are earlier reports 
in literature [160, 161] where it was shown that the release of dextran from silk 
fibroin films depends directly on the molecular weight of the polysaccharide.  
It can be concluded, that monolayer eADF4(C16) films can be used to achieve a 
prolonged release for large molecules (>30 kDa). Interestingly, after a 27% burst 
release on day 1, spider silk films released the protein BSA in a constant amount 
per day with a quasi- zero order release kinetic.  
4.3.4. SSP Monolayer Films Containing Plasticizers 
To characterize eADF4(C16) films containing 1% w/v of plasticizer (glycerol or 2-
pyrrolidone), thermograms of these films were collected as described in 3.2.8.  
The thermograms (Figure 19), showed two endothermic peaks: the first one 
corresponded to the boiling point of the plasticizer and the second one correlated 
with the spider silk protein thermal degradation.  
Interestingly, after 1 h incubation time in water, the plasticizers were completely 
washed out from the film matrix, the thermograms did not show the glycerol or 2-
pyrrolidone boiling point peak anymore. Instead, the DSC profiles resembled one 
of spider silk films without plasticizers presented in Chapter 3.  
Additionally, the protein secondary structure of spider silk films containing 
plasticizer was analyzed by FT-IR. Three different areas for every film were 
measured and three films each were considered, the average of these nine spectra 
is showed in Figure 20.  
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Figure 19: DSC thermograms of water-based spider silk films containing plasticizers 
before and after incubation for 1 h in highly purified water. 
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Figure 20: Second derivate of the FT-IR spectra of water-based spider silk films 
containing plasticizers. The two peaks indicating the presence of β–sheet structures are 
marked with an arrow. 
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The analysis of the second derivate of the FT-IR spectra of the amide I band, 
represented in Figure 20, did not detect major differences between spider silk film 
without glycerol or 2-pyrrolidone and films containing one of the two plasticizers.  
Additionally, the presence of plasticizers in the spider silk film matrix did not 
influence the content of the ß-sheet protein structures:  
 
4.3.5. SSP Films Containing Glycerol: Monolayer 
The group of Prof. Kaplan described in a preceding study [162], that the presence 
of glycerol affects the secondary structure of silk fibroin in silk films by increasing 
the content of stable silk II structures (crystalline, β-sheets). With regards to the 
data obtained in the study presented here, the content of β-sheet structures was 
already high and no alteration was observed in the secondary structure (Figure 
20). Glycerol acted as a hydrophilic plasticizer and decreased the hydrophobicity 
of the spider silk film. This leads to the solubilization of the model protein in the 
film matrix. In this way BSA was free to diffuse out with glycerol and overall the 
film released the protein more rapidly as shown in Figure 21. So, if in one hand the 
addition of glycerol in the casting solution leads to spider silk films characterized 
by higher elongation in comparison to films without plasticizer (paragraph 3.3.9, 
page53); on the other hand, its hydrophilic nature is responsible for the releasing 
80% of the encapsulated BSA after only one day, while the rest of the model 
protein was steadily released as before. 
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Figure 21: Cumulative release of FITC-BSA from water-based spider silk films 
(monolayer) and water-based spider silk films containing 1% w/v of glycerol in its 
casting formulation (monolayer 1% Gly). 
 
4.3.6. SSP Films Containing Glycerol: Multilayer and Coating 
Sandwich format films (multilayer) were prepared by compressing one spider silk 
layer which was directly loaded with FITC-BSA between two non-loaded spider 
silk films. This procedure (Method 4.2.3) permitted to obtain multilayer films by 
simply applying pressure, which resulted in an easy, quick and low priced 
manufacturing technique. One prerequisite for the successful formation of 
multilayer films was the addition of glycerol to the middle spider silk matrix, the 
one containing the model protein. The following picture  is intended to show the 
concept of the sandwich format, while Figure 23 represents the cross section of a 
spider silk sandwich created using the Method 4.2.3. 
 
Figure 22: Graphical representation of a 3-layers spider silk film design, it consists of two 
layers of water-based spider silk protein film (SSP) and one layer of a film containing 
spider silk protein, glycerol and the model protein BSA (SSP + 1% Gly + FITC-BSA).  
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Figure 23: Image obtained with a digital microscope showing the cross section of a 3-
layers (sandwich format) water-based spider silk film. The middle layer contains the 
model protein FTIC-BSA and 1% w/v of glycerol in its casting formulation. The other two 
layers are composed only by the spider silk protein eADF4(C16). 
 
As described in the previous paragraph, the incorporation of glycerol in the film 
matrix had a negative impact of the in vitro release profile of the model protein 
BSA. In order to reduce the burst release and to prolong the release of BSA, the 
model protein was embedded in a sandwich format (Figure 23). Surprisingly, the 
release of BSA from a multi-layer system resulted to be much faster than from a 
monolayer film without plasticizer as shown in Figure 24 A. The reason related to 
the presence of glycerol in the middle layer of the sandwich, the one containing 
the model drug. The external layers of the multilayer are intended to slow down 
the diffusion of the protein through the film matrix, nevertheless BSA is free to 
diffuse out from the sides where these barriers are not present. In order to seal 
the multilayer completely, the sandwich was then coated by dipping in a 
concentrated spider silk protein solution. By coating eADF4(C16) 3-layer films, 
the desired release profile close to a zero order kinetic was achieved. The coating 
completely eliminated the burst release and the release of BSA was slowed down 
neutralizing the glycerol effect (Figure 24 A). A steady release of the model protein 
over 40 days was achieved (Figure 24 B). On the other hand, a high standard 
deviation for the release profiles from different samples was recorded.  
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Figure 24: Cumulative release of FITC-BSA from coated 3-layers spider silk films 
(sandwich) and from coated spider silk film monolayer. A: 10 Days release study of FITC-
BSA, released from water-based eADF4(C16) 3-layers films (Sandwich), n=3; and from 
coated 3-layers films (Coated sandwich), n=3. B: 43 Days release study of FITC-BSA, 
model protein released from coated 3-layers films (Coated sandwich; continuation of the 
experiment shown in A), n=3; and from coated water-based eADF4(C16) films (Coated 
monolayer), n=3. 
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At this point the possibility to employ a coated monolayer, avoiding the sandwich 
preparation was considered (Figure 24 B). The same coating process was carried 
out for the monolayer containing the model protein BSA (and no glycerol). In a 
subsequent FITC-BSA release study, a reduction of the burst release compared to 
the non-coated monolayer was observed, and all samples showed reproducible 
release profiles. This film design led to an improvement of the model protein 
release (Figure 24 B). However the absence of a plasticizer affected the 
mechanical properties. Coated monolayers were very brittle and difficult to 
handle.  
Therefore, in a next step, it was investigated whether it was possible to coat the 
monolayer containing both the model protein BSA and the plasticizer glycerol 
(Figure 26). This resulted in an extreme decrease of the burst release of BSA (from 
50% to 21%) and in a prolonged release of the model protein to over 90 days as 
shown in Figure 25. 
 
 
Figure 25: Cumulative release of FITC-BSA from water-based spider silk films containing 
1% w/v of glycerol in its casting formulation (monolayer + glycerol) and from coated 
water-based spider silk films containing 1% w/v of glycerol in its casting formulation 
(coated monolayer + glycerol). 
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Figure 26: Image of a water-based spider silk film containing glycerol and the model 
protein FITC-BSA coated with eADF4(C16). Bar = 250 µm 
 
4.3.7. Coating Characteristics 
There are different methods in order to process silk materials into coatings, all of 
them have been presented in a recent review [125]. The techniques used so far 
include: casting, dip coating, spin coating, electrodeposition, electrospinning, 
spraying and other printing methods such as lithography. In the work presented 
in this chapter, dip coating was employed as method to seal spider silk film into a 
spider silk “capsule” (Method 4.2.4). The main aim of the coating is to act as 
mechanical barrier by retarding the diffusion of the drug out of the film matrix. 
Spider silk films loaded with the model protein FTIC-BSA were coated with 
different concentration of spider silk: 10, 25 and 50 mg/mL. The thicknesses of the 
resulting coatings are listed in Table 15.  
Table 15: Thickness of different coatings 
 
eADF4(16) Film containing: 
eADF4(C16) 
coating solution 
N° of films 
considered 
Thickness 
(µm) 
FITC-BSA 1% w/v 1 2 
FITC-BSA 2.5% w/v 6 9.17 ± 6.6 
FITC-BSA 5% w/v 4 15.75 ± 7.6 
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As discussed before, the secondary structure of the protein eADF4(C16) plays a 
major role in defining the film properties (Chapter 3). For this reason, the coatings 
were analyzed using the FT-IR microscope (Method 3.2.6). All the coatings were 
characterized by a high content in β-sheet structures, the higher concentrated 
coating (50 mg/mL) showed a higher intensity of the β-sheet peak at 1625 cm-1 
(Figure 27). Since a higher content in β-sheets leads to a water insoluble and more 
stable silk protein matrix [146, 163], the spider silk solution of 50 mg/mL was 
chosen as preferred concentration for the coating solution.  
 
 
Figure 27: Second derivative FT-IR spectra of water-based spider silk films coated with 
different concentration of spider silk. 
 
During the time needed for the coating to dry, the solid surface of the spider silk 
film was in direct contact with the coating solution phase creating a solid-liquid 
interface. In order to investigate if during this time frame the protein BSA 
presented in the film surface diffuses into the liquid coating, remains entrapped 
once the coating has dried, spider silk films containing the model protein were 
incubated in the liquid coating adapting the Method 4.2.2 for this simulation. The 
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presence of FITC-BSA in the coating solution was monitored by fluorescence 
spectroscopy and the quantity of the diffused BSA was calculated using a 
calibration curve (prepared using different FITC-BSA concentration dissolved in 
50 mg/mL spider silk solution). Figure 28 shows the diffusion of BSA into the 
coating solution.  
 
 
Figure 28: Simulation of FTIC-BSA diffusion from water-based spider silk films into the 
eADF4(C16) 50 mg/mL coating, n = 3.  
 
After 3 h, about 25% of the BSA was released into the coating solution from the 
film matrix. The results of this experiment show that during the coating 
processing a small quantity of the model protein diffuses from the silk film into 
the coating. These data correlated well with the 20% burst release shown in 
Figure 24 and Figure 25. Most likely, the initial burst release was caused by the 
presence of BSA in the coating. 
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4.3.8. SSP Monolayer Films Containing 2-Pyrrolidone   
In the last part of this study, the possibility to replace the plasticizer glycerol with 
2-pyrrolidone was considered. eADF4(C16) monolayers containing the model 
protein FITC-BSA and 1% w/v 2-pyrrolidone were cast. The incorporation of this 
particular plasticizer led to an improvement of the film mechanical properties 
increasing 70 times the elasticity of the film (Table 12). Once the films were 
incubated in PBS buffer, films started to release the model protein with a similar 
kinetic recorded for the spider silk monolayers without plasticizers (Figure 30). 
This result is interesting in that the use of 2-pyrrolidone did not escalate the initial 
burst release as glycerol did (Figure 29). This effect may be explained by the 
difference between glycerol and 2-pyrrolidone. Glycerol has a logP value of -1.8 
and is therefore more hydrophilic compared to 2-pyrrolidone, which has a logP of 
-0.9). Hence, glycerol may be able to coordinate more water molecules as it has 
three hydrogen bond acceptor groups, whereas 2-prrolidone only has one 
hydrogen bond acceptor group.  
 
Figure 29: Cumulative release of FITC-BSA from water-based spider silk films containing 
different concentration of plasticizers. Release of FITC-BSA from eADF4(C16) films 
containing respectively 0.5, 1 and 3% w/v of glycerol, n = 3 for each condition. 
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Figure 30: Cumulative release of FITC-BSA from water-based spider silk films containing 
different concentration of plasticizers. Release of FITC-BSA form eADF4(C16) films 
containing respectively 0.5, 1 and 3% w/v of 2-pyrrolidone, n = 3 for each condition.  
 
In order to further decrease the 20% burst release occurring at day one, films 
containing 2-pyrrolidone were coated with eADF4(C16) (Figure 32). Interestingly, 
the coating did not affect the release of BSA (Figure 31). A large burst release of 
20% implicated that a substantial portion of the encapsulated molecule was 
released rather fast. This phase was followed by a sustained release of the 
molecule. In some cases it was stated that a zero-order release kinetic is not 
necessary to create a DDS for sustained release of drugs [164]. The plasticizer 2-
pyrrolidone has a higher logP (-0.9) in comparison to glycerol (-1.8). Therefore, 
the incorporation of 2-pyrrolodone did not influence the release of BSA as 
previously described for glycerol. The replacement of glycerol with 2-pyrrolidone 
allowed the formation of a spider silk monolayer which showed good mechanical 
properties and an interesting in vitro release profile, where the bust is limited to 
20%. Additionally, this last film design did not require a coating to slow down the 
release of BSA. In conclusion, spider silk films can be designed as monolithic 
matrices where a drug is homogenous dispersed. Consequently, the release 
depends on the drug diffusion in the silk matrix. In accordance with the findings  
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presented here, it is conceivable to consider the release in vitro of a biomolecule 
from eADF4(C16) films following the Higuchi law [165]. In fact, if the fraction of 
the released BSA is plotted against the root square of the time, the linear 
regression has a coefficient of determination (R2) of 0.9976 for the monolayer and 
a R2 of 0.9971 for the monolayer containing 1% w/v 2-pyrrolidone. The films 
involved in this study were used for in vitro release studies directly after 
preparation. Therefore a study considering the possible effect of storage on the 
release profiles should be considered in the future. 
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Figure 31: Release of FITC-BSA from different water-based spider silk film films: films 
containing the plasticizer glycerol (monolayer, 1% w/v glycerol), n=3; coated spider silk 
films containing glycerol (coated monolayer, 1% w/v glycerol), n=4; films containing the 
plasticizer 2-pyrrolidone (monolayer, 1% w/v 2-pyrrolidone), n=4; coated spider silk 
films containing 2-pyrrolidone (coated monolayer, 1% w/v 2-pyrrolidone), n=4; and 
finally spider silk films without excipients (monolayer), n=4. 
 
 
80 
 
 
Figure 32: Image of a water-based spider silk film containing 2-pyrrolidone and the model 
protein FITC-BSA, coated with eADF4(C16). Bar = 250 µm 
 
 
4.3.9. Biodegradation of SSP Films 
One of the great advantages of using eADF4(C16) proteins in developing depot 
systems is the biodegradability of this protein material. Once the film will be 
implanted, the spider silk matrix will be slowly cleaved by proteases. The 
degradation of the spider silk depot system will avoid any additional surgery 
necessary to remove the DDS. Furthermore, the biodegradation of a DDS is an 
important characteristic because it can affect drug release kinetics [166].  
A multiphase release mechanism for silk matrix was described by Hines and 
Kaplan [161]. The silk multiphase release is first defined by a phase of diffusion 
and then followed by a phase of degradation of the silk protein matrix, which is 
very similar to the mechanism reported for poly(lactic-co-glycolic acid) (PLGA) 
materials [161]. Silk is an important alternative to PLGA and the advantage of 
using silk materials lies in the fact that silk will degrade slower than PLGA [161]. 
Moreover, degradation of PLGA-based DDS can affect the local area where it is 
implanted, such as changing the local pH [167] or even stimulate an undesired 
immune response [168-170].  
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As a preliminary proof of the enzymatic degradation, spider silk films containing 
2-pyrrolidone as plasticizer were incubated at 37°C with a buffer solution 
containing elastase and trypsin, while other films were incubated only in PBS. 
Elastase is a protease that cleaves specific peptide bonds on the carboxyl side of 
small, hydrophobic amino acids such as glycine, alanine, and valine. The presence 
of trypsin was necessary to produce the active form of elastase [65].  
Figure 33 presents the loss in mass of spider silk films during the experiment.  
 
 
Figure 33: Mass of spider silk protein films containing 1% v/w 2-pyrrolidone during the 
biodegradation experiment. The “SSP-Films/PBS” group refers to the films incubated in 
PBS buffer as control group; while the “SSP-Films/Enzymes” group refers to the films 
incubated with a PBS buffer containing the two enzymes elastase and trypsin. After 10 
days the enzymes’ concentration was increased five times (red line) in order to highlight 
the difference in mass loss between the two groups. 
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After the first day of incubation, both films incubated with enzymes and films 
incubated only in PBS buffer, showed a drop in weight, caused by the washing out 
of the plasticizer 2-pyrrolidone. After that, during the 10 days of the study no 
differences were noted between the two groups and films degraded very slowly. 
The films incubated with the enzymes lost about 6% of their mass from day 1 to 
day 10. At that rate, four months would be needed to completely degrade the 
spider silk film matrix.  
Increasing five times the enzymes concentration after day 10, led to a substantial 
drop in the mass of the films incubated with elastase, and a remarkable difference 
between the two groups was observed. With this set up, only about one month 
would be needed to completely degrade the eADF4(C16) films.  
Scanning electron micrographs (Figure 34) were additionally acquired to 
document the degradation observed in this experiment. At the beginning (Figure 
34 A; B) the eADF4(C16) film was characterized with a very smooth and 
homogeneous surface. At the end of the experiment, after 16 days, pores were 
visible on the film surface (C; D; E; F). SEM micrographs of the film incubated with 
elastase (E; F) showed more and larger pores compared to films incubated only in 
PBS buffer (C; D), suggesting the degradation action of the protease. In conclusion, 
the enzymatic degradation of spider silk films, takes place in presence of elastase 
and it highly depends on the protease concentration. Appropriate in vivo studies 
are necessary to better elucidate the biodegradation mechanism and its kinetic, as 
they were carried out in the past for PLGA materials [24, 171, 172]. 
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Figure 34: Scanning electron micrographs of spider silk films containing 1% v/w 2-
pyrrolidone before and after biodegradation. A: spider silk film´s surface before 
biodegradation, bar = 10 µm; B: spider silk film´s surface before biodegradation, bar = 1 
µm; C: spider silk film´s surface after biodegradation, control group, incubated in 
phosphate buffer, bar = 10 µm; D: spider silk film´s surface after biodegradation, control 
group, incubated in phosphate buffer, bar = 1 µm; E: spider silk film´s surface after 
biodegradation, enzymes group, incubated in phosphate buffer containing elastase and 
trypsin, bar = 10 µm; F: spider silk film´s surface after biodegradation, enzymes group, 
incubated in phosphate buffer containing elastase and trypsin, bar = 1 µm. 
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4.4. Conclusion 
This Chapter investigated the potential of spider silk films as drug delivery 
matrices. The evaluation started with the loading of a variety of drugs exploring 
two different loading techniques: the remote and direct loading. The remote 
loading occurred due to electrostatic and hydrophobic interactions. Therefore, 
this type of loading is ideally recommended for those drugs having a high logP and 
a strong opposite charge from the spider silk protein. On the contrary, the direct 
loading is only applicable to those drugs that do not interact with the spider silk 
protein in solution.  
Drug release from direct-loaded eADF4(C16) films was found to be directly 
related to the molecular weight of the drugs. This release behavior could be 
advantageous in cases where a small molecule needs to be released immediately 
from a DDS, e.g. for local, topic, or targeted delivery. On the contrary, larger 
molecules, as therapeutic proteins, may show a prolonged release from the spider 
silk films. The incorporation of a plasticizer in the film matrix was necessary to 
improve its mechanical properties. The presence of glycerol in eADF4(C16) layers 
affected the films properties tremendously. Although the incorporation of this 
plasticizer improved the film elongation, it also accelerated the release of the 
model protein BSA. On the contrary, the use of 2-pyrrolidone did not increase the 
burst release, nor did it lead to a fast continuous release.  
Coating the films with concentrated eADF4(C16) protein solution counterbalanced 
in part the negative effect of glycerol on the release of BSA. It was possible to 
produce sandwich format films by compressing different eADF4(C16) layers, 
when the middle layer contained glycerol. This process was an easy, quick, and 
low priced manufacturing technique. The production of multilayer films could be 
advantageous in cases where the quantity of the drug loaded in one monolayer is 
not sufficient to obtain a therapeutic effect; or when it is necessary to load 
different drugs which are incompatible together. Incompatible drugs could be 
loaded in separate layers and then it would be possible to combine the different 
layers together. Another opportunity could be to create a multilayer composed by 
layers having different properties and scopes. A monolayer containing 2-
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pyrrolidone as plasticizer on the other hand, is easy to prepare, has good 
mechanical properties and can release a protein in a sustained manner over three 
months. It was a slow biodegradable film and this particular spider silk film 
composition is a promising protein drug delivery matrix. Such film could be used 
for several pharmaceutical and medical purposes, especially in situations in which 
the mechanical strength of a drug eluting matrix is of high relevance. 
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5. Scale-up process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
5.1. Introduction 
As it has been discussed in the general introduction, spider silk proteins for 
applications in drug delivery have attracted an increased interest during the past 
years. Some possible future medical applications for this biocompatible and 
biodegradable material include scaffolds for tissue engineering, implantable drug 
delivery systems and coatings for implants. The most adopted method to cast 
spider silk films remains the solvent evaporation technique (Paragraph 1.5, page 
23). Since this technology is already integrated in cast film lines in industry, it is in 
principle easy to adapt from lab-scale to industrial production. But so far, the 
solvent evaporation technique for spider silk films has only been used in lab scale 
by direct casting into PTFE forms. Challenges of this manual process are the 
variation in films thickness and the control of film geometry. Additionally, the 
number of films produced per time is very limited.  In the previous chapter, the 
preparation of water-based spider silk films for drug delivery applications was 
shown. The work reported in this chapter describes the development of a 
manufacturing technique for casting larger spider silk films from aqueous solution 
employing a film applicator. Films were characterized in terms of morphology, 
water solubility, protein secondary structure, thermal stability, and mechanical 
properties. Since the water-based films were first soluble in water, different post-
treatments were evaluated (phosphate ions, ethanol, steam sterilization and water 
vapor) to increase the content of β-sheets to achieve water insolubility. Finally, the 
mechanical properties of the spider silk films were notably improved by 
incorporating 2-pyrrolidone as plasticizer. 
5.2. Methods 
5.2.1. Film Production 
Spider silk proteins were dissolved in 6 M guanidinium thiocyanate and 
subsequently dialyzed against 5 mM Tris/HCl buffer, pH 8 at 4°C. The pH of the 
protein solution was determined using a pH meter MP 220 (Mettler Toledo, 
Giessen, Germany). The protein solution was centrifuged at 4°C for 15 min at 
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10,000 rpm and subsequently filtered through a 0.45 μm cellulose acetate filter. 
Afterwards, the spider silk solution was dialyzed against 5 mM Tris/HCl buffer, pH 
8 at 4°C, containing 10% w/v of PEG 20,000 Da. Protein concentration was 
determined photometrically using a NanoDrop 2000 system from peqlab 
(Erlangen, Germany). The protein concentration of the casting solution was finally 
adjusted to 5% w/v adding 5 mM Tris/HCl buffer. Spider silk films were cast on a 
plastic foil A5 22/5B from mtv-messtechnik (Koeln, Germany) at room 
temperature using a film applicator Coatmaster 510 (Erichsen, Hemer, Germany) 
equipped with a casting knife of 2000 μm. Casting was performed at a velocity of  
1 mm/sec. 2 mL of the casting solution were used to cast each film. The surface 
coverage was about 100 cm2. The film applicator was placed in a laminar flow 
cabinet (Thermo scientific, Munich, Germany). After preparation, films were dried 
overnight at room temperature in the laminar flow cabinet which was closed and 
switched off. Finally, films were cut into samples of 2.5 x 3 cm using a scalpel. 
Films containing 2-pyrrolidone were prepared dissolving 2% w/v of the 
plasticizer directly in the casting solution. 
5.2.2. Spider Silk Film Morphology 
Photographs of eADF4(C16) films were obtained using a digital camera DSC-S75 
(Sony Corporation, Tokyo, Japan). Scanning electron micrographs of the film 
surface were collected after the films were immobilized on Leit-Tabs (Plano 
GmbH, Wetzlar, Germany) to a sample holder. Samples were carbon sputtered 
under vacuum and analyzed using a Joel JSM-6500F field emission scanning 
electron microscope (Joel Inc., Peabody, USA). SEM pictures were collected with 
the support of Christian Minke. 
5.2.3. Thermal Analysis 
Thermograms of spider silk films were obtained by differential scanning 
calorimetry (DCS 204 Netzsch, Selb, Germany). Spider silk films were loaded in 
aluminum pans and a small hole was punched in the pan covers. Samples were 
heated under nitrogen flow at 10 K/min up to 110°C, then cooled to -40°C, 
followed by heating to 400°C as described previously [145].  
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5.2.4. Protein Secondary Structure 
Fourier transform infrared (FT-IR) spectra were collected using the Hyperon 
microscope from Bruker Optik (Bruker, Germany) using a 20x attenuated total 
reflectance objective (ATR). The spectra were an average of 120 scans at the 
resolution of 4 cm-1. All measurements were performed in the range of 600 and 
4000 cm-1. Films were measured in three different areas: in the middle, next to the 
edge and between the middle and the edge.  
5.2.5. Dissolution of spider silk protein from cast films in water 
Films were weighed using a balance AT261 Delta Range from Mettler Toledo 
(Giessen, Germany) and placed in a 6-well plate. Each film was covered with 2 mL 
of highly purified water (HPW). The well plate was positioned on a shaking plate 
at 2 rpm at room temperature. After 1 h, the water was removed and analyzed 
using a spectrophotometer (Agilent 8453, Boeblingen, Germany). Protein 
concentration in solution was determined photometrically. The amount of the 
dissolved spider silk was compared with the initial mass of the film obtaining the 
percentage of the loss in mass of the film in water. 
5.2.6. Post-treatments 
5.2.6.1. PO43- Post treatment 
Films were post-treated by spraying a 2 M phosphate solution on the film surface 
using an ultrasonic nozzle Sonotek 120-00456 (Sonotek, Milton, USA) at a flow 
rate of 1 mL/min at 120 kHz for10 seconds. Post-treated films were left to dry at 
room temperature under laminar flow. 
5.2.6.2. Ethanol Post-treatment 
Films were post-treated by spraying a 70% ethanol-water solution on the film 
surface using an ultrasonic nozzle Sonotek 120-00456 (Sonotek, Milton, USA) as 
described above. Post-treated films were left to dry at room temperature under 
laminar flow. 
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5.2.6.3. Steam Sterilization  
Spider silk films were steam sterilized using an autoclave GTASO (Fritz Goessner 
GmbH&Co, Hamburg, Germany). Briefly, air was saturated with water vapor, then 
the temperature was raised to 121°C, 1 bar, held for 15 min, and finally the system 
was cooled down to room temperature. 
5.2.6.4. Water Vapor Treatment 
Spider silk films were sealed in autoclave bags and stored for 60 min in a 
desiccator (Figure 35). The desiccator’s reservoir was filled with highly purified 
water preheated at 60°C. The temperature was monitored using a digital 
temperature and humidity sensor (TFA Dostmann, Wertheim-Reicholzheim, 
Germany).  
 
 
Figure 35: Water vapor treatment. 
 
5.2.7. Mechanical Properties 
Films were cut into samples of 2x120 mm. The thickness was determined using a 
Mitutoyo pen (Mitutoyo Deutschland GmbH, Neuss, Germany). Tensile test of 
spider silk films (n=5) were carried out at 24°C and 32% RH; spider silk films 
containing 2% w/v 2-pyrrolidone (n=5) were analyzed at the same conditions. All 
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spider silk films were tested in a dry state. Measurements were performed using a 
Zwick tensile tester Z0.5 (Zwick GmbH & Co. KG, Ulm, Germany), equipped with a 
5 N capacity load cell. The mechanical properties measuraments were carried out 
with Michael Bergfield from AmSilk. 
 
5.3. Results and Discussion 
 
5.3.1. The Scale up Process 
The film applicator used in this work is represented in Figure 36.  The device is 
controlled by a microprocessor and has an adjustable drawing speed in the range 
of 0.1 - 19.9 mm/s. Additionally it has an integrated vacuum function to adhere 
substrates on its working surface. The casting solution was loaded in the casting 
knife and the automatic arm moved the casting knife forward on the substrate. 
The thickness of the resulted film was mainly determined by the casting solution 
properties (e.g. protein concentration, viscosity and surface tension), by the 
velocity of the automatic arm, and the size of the casting knife. In principle the 
process is representative of large scale film casting systems that are able to 
produce hundreds/thousands of square meters of film pro day. 
In this study, spider silk films were cast from aqueous solvent and transparent, 
homogenous films with a visible smooth surface in the dimensions of 90 cm2 were 
obtained. The geometry and the number of the films produced in one casting step 
were adjusted by cutting the larger film with a scalpel. The process allowed a 
reproducible production of spider silk protein films. In Figure 37, a photograph of 
eADF4(C16) film samples and in Figure 38 the respective SEM micrograph are 
presented. Compared to manually casted films described previously in Chapter 3, 
a notable difference is the film thickness. The main difference between the 
manually cast films and films cast with the film applicator regards the water 
solubility of the films. Films cast from aqueous solution using the film applicator 
dissolve almost immediately, indicating that the protein structure within the film 
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is different compared to manually cast films which are not water soluble, although 
having the same composition [144].  
 
Figure 36: Film applicator Coatmaster 510, modified and reproduced with permission of 
erichsen 
 
 
 
Figure 37: Photograph of eADF4(C16) spider silk film cast using the film applicator. Same 
film photographed from different angles leading to a different light reflection.  
Bar = 1 cm 
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Figure 38: Scanning electron micrographs of spider silk films cast using the film 
applicator. A: bar = 10 µm; B: bar = 1 µm. 
 
Besides the difference in thickness and protein concentration, the main difference 
between the manually cast films and films cast using the film applicator occurred 
regarding water solubility of the films. Films cast from aqueous solution using the 
film applicator dissolved almost immediately, indicating that the protein structure 
within the film may differ compared to manually cast films. In order to understand 
this new behaviour, the protein secondary structure has been investigated. 
5.3.2. Protein Secondary Structure 
As discussed earlier (Paragraph 3.2.6), the properties of spider silk protein films, 
including water solubility, are mainly influenced by the secondary structure of the 
spider silk protein. Two analytical tools selected at the beginning of this work to 
characterize the protein secondary structure within the film matrix were: DSC 
(Method 3.2.8) and FT-IR (Method 3.2.6).  
Thermograms of eADF4(C16) films cast with the film applicator represented in 
Figure 40 are different from the ones obtained for films cast manually in Chapter 
3, page 46. In fact, in this work the thermograms showed an exothermic peak 
around 220°C, which was not previously noted in the films cast manually [144]. 
This particular peak is correlated with the formation of β-sheet structures induced 
by temperature [145].  
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Figure 39: Thermogramms of spider silk films cast using the film applicator (n=4). 
 
This is a first indication that the secondary structure of the eADF4(C16) proteins 
composing the film matrix had changed upon manufacturing. The endothermic 
peak around 330°C represents the decomposition of the protein.  
Moreover, spider silk films cast using the film applicator showed two different 
secondary structure trends as highlighted in Figure 40.  
 
 
Figure 40: Second derivate of the FT-IR spectra obtained from spider silk films produced 
using the film applicator. Left: spectra obtained analysing three different areas of 6 
different spider silk films cast using the film applicator. Right: average of the 18 spectra. 
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The first trend resembles the spectra recorded for the films cast manually [144], 
which is characterized by the two typical peaks of β-sheets structures (1690 cm-1 
and 1625-1640 cm-1). The second profile clearly showed these peaks shifted 
closer to the β-turn (1660-1685 cm-1) and random coil regions (1652-1660 cm-1). 
This indicates that within the same film, it is now possible to detect areas 
characterized by a high content of β-sheets and areas having low content of β-
sheets structures. In conclusion, both DSC thermograms and FT-IR analysis show a 
change in the type of secondary structures in the spider silk film cast using the 
film applicator. One possible explanation may be the difference in drying time of 
the casting solution. The casting solution spread on the surface by the film 
applicator results in a thinner layer in comparison with the layer deposited 
manually. The spider silk proteins do not have sufficient time to fold in organized 
structures. Another reason may be the difference alignment of the protein chains 
due to the film applicator fluid dynamics, where more time is needed in order to 
rearrange the random entanglement of the protein chains from a more laminar 
orientation immediately after casting. Consequently, in order to increase the 
content of water insoluble regions within the film matrix, a post-treatment needed 
to be introduced following the casting process. 
5.3.3. Post-treatments 
In the past, different methods have been tested and investigated in order to 
increase the content of β-sheet structures in silk films. The most commonly used 
post-treatments are: kosmotropic ions, alcohol, high temperature, and water 
vapor [48]. An alternative treatment consists of immersing silk films in water, the 
so called water-annealing [173, 174]. However, this method cannot be applied to 
the spider silk films because the films will dissolve instantaneously before any 
changes in the protein secondary structure can occur. Another treatment option 
implicates the treatment of films with high temperature. As shown in Figure 39, 
heating of cast films to 220°C can trigger the formation of β-sheet structures. 
However, this may result in possible damage to drugs (such as proteins and 
peptides) incorporated in the film matrix.   
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In this study, the following post-treatments have been investigated: phosphate ion 
and ethanol treatment using an ultrasonic nozzle, steam sterilization, and water 
vapor treatment.. 
5.3.3.1. Phosphate Ions Treatment 
Water-based spider silk particles characterized by high β-sheets content have 
been already prepared using a salting-out process, where potassium phosphate 
was used as lyotropic salt [65, 67, 158, 175, 176]. Furthermore, spider silk films 
cast from organic casting solution such as hexafluoroisopropanol (HFIP) have 
been incubated in solutions containing phosphate ions to obtain water insolubility 
[147, 152]. In this work water-based eADF4(C16) films cast with the film 
applicator where post-treated by spraying a phosphate solution on the film 
surface using an ultrasonic nozzle. However, the method had a negative impact on 
the films. The formation of salt crystals on the film surface after drying combined 
with the low thickness, resulted in breaking most of the films treated. Figure 41 
shows how the spider silk film looks like before and after the treatment.  
 
 
Figure 41: Pictures of spider silk films produced using the film applicator before (left) and 
after (right) the phosphate ions post-treatment. 
 
5.3.3.2. Ethanol Treatment 
The most commonly used post-treatment to convert the water soluble silk fibroin 
type I structure to the water insoluble silk fibroin II structure is the immersion of 
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silk materials in methanol mixtures [160, 173, 174, 177-179]. This practice has 
been also applied on acid-based spider silk films in the past [143, 146, 147, 152]. 
To avoid using methanol as a solvent, this work considered the replacement of this 
particular alcohol with ethanol. A mixture of 70% v/v ethanol has been previously 
employed to sterilize silk fibroin films [173] and to treat silk fibroin membranes 
[180]. Moreover, Xin Chen at al. tested different ethanol concentrations and found 
out that using 70% ethanol resulted in an immediate increase of β-sheet 
structures in silk fibroin films [181]. In this study, the ethanol solution was 
sprayed on the film surface employing an ultrasonic nozzle. This method allows 
covering the film surface with a thin layer of ethanol which quickly evaporates. An 
example of treated film is shown in Figure 42.  
 
Figure 42: Pictures of spider silk films produced using the film applicator before (left) and 
after (right) the ethanol post-treatment. 
The processed films were analyzed by DSC and FT-IR to evaluate changes in the 
protein secondary structures (Figure 43). The DSC-thermograms did not show any 
exothermic peak at 220°C, meaning that a phase transition from unordered 
structures (such as helices, β-turns, random coils) to ordinate structures (β-
sheets) did not take place because the content in β-sheets was already high. This 
assumption was then confirmed by FT-IR measurements (Figure 43).  
It has been shown that most of the spider silk film dissolution in water occurs 
during the first hour, after that, the protein film matrix results to be water stable 
[144]. For this reason, three films were incubated in water for 1 h.  
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Figure 43: Left: DSC-thermograms of spider silk films produced using the film applicator 
after the ethanol post-treatment, Exo ↓, n=3. Right: Second derivate of the FT-IR spectrum 
obtained from spider silk films produced using the film applicator after ethanol post-
treatment. The presented spectrum is the average of 18 spectra recorded from 6 different 
films. Every film was analysed in three different areas. 
Only 0.72 ± 0.06% w/w of the film matrix dissolved. In conclusion, the method 
presented here was successfully able to increase the content in β-sheets resulting 
in water-based spider silk films cast using the film applicator stable in water. On 
the other hand, working further with ethanol will jeopardize the aim of producing 
organic solvent free spider silk films. 
5.3.3.3. Steam Sterilization  
Consulting the decision trees document prepared from the European Agency for 
the Evaluation of Medicinal Products (EMA) for the selection of sterilization 
methods, it is clear that the autoclave treatment is the preferred method for final 
sterilization [182]. The autoclave combines both heat and vapor, which both could 
be beneficial to increasing the content of β-sheets within the spider silk film 
matrix. Moreover, this method has been already successfully tested on 
eADF4(C16) submicron and micron particles [158]. In Figure 44, an optical image 
is provided showing the appearance of spider silk films after autoclave treatment. 
As performed before in the case of the ethanol post-treatment, the presence of β-
sheets in the autoclaved spider silk matrix was investigated by DSC and FT-IR 
(Figure 45). 
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Figure 44: Pictures of spider silk films produced using the film applicator before (left) and 
after (right) the autoclave post-treatment. 
 
Additionally the water solubility was also assessed. The autoclave treatment was 
able to increase the presence of water insoluble β-sheet structures. DSC 
thermograms showed the absence of any exothermic peaks, while FT-IR analysis 
highlighted the two major peaks for β-sheet structures (1690 cm-1 and 1625-1640 
cm-1). Finally, the autoclaved films were stable upon incubation in water, since 
after 1 hour incubation in water, only 1.10 ± 0.64% w/w of three film matrices 
dissolved. Steam sterilization can achieve two purposes in one step, is able to 
convert water soluble spider silk films in water stable matrices and provides final 
sterilization of films. 
 
Figure 45: Left: Thermograms of spider silk films produced using the film applicator after 
autoclave post-treatment, Exo ↓, n=3. Right: Second derivate of the FT-IR spectrum obtained 
from spider silk films produced using the film applicator after autoclave post-treatment. The 
presented spectrum is the average of 18 spectra recorded from 6 different films. Every film 
was analyzed in three different areas. 
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5.3.3.4. Water Vapor Treatment 
In the previous paragraph, it has been shown that the combination of heat and 
vapor can increase the content of β-sheets within eADF4(C16) film matrices cast 
using the film applicator. Nevertheless, the autoclave treatment is not applicable if 
sensitive drugs are encapsulated in the film. Recently, it has been shown that 
eADF4(C16) films are promising therapeutic proteins delivery systems [144]. 
Since the temperature would damage this sensitive class of actives [183-185], the 
autoclave treatment can be considered neither for final sterilization nor for 
increasing the content of water insoluble silk protein structures. Hence, the last 
post-treatment investigated in this work concerns the exposure of spider silk films 
to a high relative humidity environment, without the application of high 
temperature. In the past, silk fibroin particles have been treated with 89% or 96% 
RH for 24 h [178, 186], while fibroin films have been processed with >90% RH for 
12 h [187]. Moreover, silk fibroin films have been also placed in dedicated 
containers partially filled with water, where vacuum has been applied for 6  [177] 
and 5 h [174]. The method employed in this project was designed in order to 
decrease the time of treatment to 1 h, to avoid the use of vacuum, and therefore 
allowing later scale-up of the method forwards a semi-continues production 
process. A schematic representation of the method setup is provided in Figure 35, 
page 90. Temperature and relative humidity obtained during the post-treatment 
are listed in Table 16.  An optical image of the spider silk films is provided in 
Figure 46. Film analysis by DSC and FT-IR revealed the presence of a high β-sheets 
content as represented in Figure 47. The extraction of spider silk protein of 
treated films after 1 h incubation in water was measured as 0.94 ± 0.36% w/w. 
The water vapor treatment resulted to be an efficient, quick and simple method to 
increase the β-sheets content in eADF4(C16) films. Furthermore, during the 
treatment the temperature never raised above 33°C (Table 16), suggesting the use 
of this method in cases where spider silk films are loaded with temperature 
sensitive drugs. 
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Table 16: Temperature and relative humidity (RH) measured during the water vapor 
treatment. 
 
 
 
 
 
 
 
Figure 46: Pictures of spider silk films produced using the film applicator before (left) and 
after (right) the water vapor post-treatment. 
 
 
Figure 47: Left: Thermograms of spider silk films produced using the film applicator after 
the water vapour post-treatment, Exo ↓, n=3. Right: Second derivate of the FT-IR spectra 
obtained from spider silk films produced using the film applicator after the water vapor 
post-treatment. The presented spectrum is the average of 9 spectra recorded from three 
different films. Every film was analyzed in three different areas. 
Films treated 
(n°) 
Time of treatment 
(min) 
Temperature  
(°C) 
RH  
(%) 
10 60 33 78 
12 60 33 74 
12 60 32 75 
14 60 33 77 
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5.3.4. Increasing the Mechanical Properties of Spider Silk Films 
cast using the Film Applicator 
Dry non-treated films cast with the film applicator were characterized by a rather 
low elongation (Table 17).  
 
Table 17: Tensile test of different spider silk films, cast using the film applicator. h: 
thickness Et: elastic modulus; σB: tensile strength at break; εB: elongation at break (% 
over the initial length). 
FILM h (μm) Et (MPa) σB (MPa) εB (%) 
eADF4(C16)  13 ± 2 885 ± 140 18.3 ± 2.06 2.1 ± 0.17 
eADF4(C16)  + 2-pyrrolidone 14 ± 2  497 ± 103 13.2 ± 1.48 77 ± 14 
 
Spider silk films containing 2-pyrrolidone as plasticizer had a 35 times higher 
elongation in comparison with films without 2-pyrrolidone, as shown in Table 17. 
The water vapor treatment method was now also evaluated for eADF4(C16) films 
containing the plasticizer 2-pyrrolidone. Figure 48 reports the thermograms and 
the FT-IR spectra obtained from the films before and after post-treatment.  
DSC scans, before the water vapor treatment (Figure 48 left up), reveled two 
endothermic peaks: the first one is correlated with the presence of the plasticizer 
and the second one is related to the degradation of the film matrix.  
In this particular case it is not possible to observe the exothermic peak of the β-
sheets formation, since the endothermic peak of 2-pyrrolidone is covering it. After 
the vapor treatment (Figure 48 bottom left) it is possible to discriminate the same 
two peaks again. FT-IR analysis highlighted the increment of β-sheets after the 
treatment, represented by the disappearance of the peak at 1650 cm-1 and the 
increment of the peak at 1624 cm-1 (Figure 48 top to bottom right). 
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Figure 48: Top left: Thermograms of spider silk films containing 2-pyrrolidone produced 
using the film applicator before the water vapour post-treatment, Exo ↓, n=3. Bottom left: 
Thermograms of spider silk films containing 2-pyrrolidone produced using the film 
applicator after the water vapor post-treatment, Exo ↓, n=3. Top right: Second derivate of 
the FT-IR spectra (amide I) obtained from spider silk films containing 2-pyrrolidone 
produced using the film applicator before the water vapour post-treatment. The 
presented spectrum is the average of 9 spectra recorded from three different films. Every 
film was analyzed in three different areas. Top right: Second derivate of the FT-IR spectra 
(amide I) obtained from spider silk films containing 2-pyrrolidone produced using the 
film applicator after the water vapor post-treatment. The presented spectrum is the 
average of 9 spectra recorded from three different films. Every film was analyzed in three 
different areas. 
 
In conclusion, it is possible to improve the mechanical properties of water-based 
spider silk films cast using the film applicator by incorporating 2-pyrrolidone, and 
water stability of the films can be achieved by water vapor treatment. 
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5.4. Conclusion 
 
In this work, water-based spider silk films have been produced using an automatic 
film applicator. These films have a visible better appearance, a smoother and more 
uniform surface, compared to films cast manually. The analysis of the secondary 
structure of eADF4(C16) proteins within the film matrix revealed the poor 
presence of β-sheet structures. This resulted in films which are no longer water 
stable. In order to increase the content in β-sheets and produce water insoluble 
films, different post-treatments have been investigated. Among all the tested 
treatments (phosphate ions, ethanol, steam sterilization and water vapor), water 
vapor was the one that showed the most promising results. Further, it has been 
assessed that the incorporation of 2-pyrrolidone in the film matrix can improve 
the mechanical properties of the spider silk films. These films can also be treated 
with water vapor in order to achieve water insolubility. In conclusion, the solvent 
evaporation method presented in this paper allows the production of larger spider 
silk films, which are visibly transparent and flat. The scale-up production of these 
films is easy and possible as both casting and water vapor treatment can be 
carried out in available industrial equipment. Industrialization could lead to the 
development of spider silk-based products such as scaffolds for tissue 
engineering, implantable drug delivery systems, and coatings for implants with 
improved biocompatibility. 
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6. Proof of Concept: SSP Films for 
Delivery of Therapeutic Proteins  
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6.1. Introduction 
 
The previous chapters described how to manufacture water-based spider silk 
films. The process presented in this thesis enables the encapsulation of large 
biomolecules, such as proteins, directly in the spider silk film matrix (Chapter 4). 
These biocompatible and biodegradable films can be produced in large scale using 
a film applicator, as seen in Chapter 5. Furthermore, these films have been 
investigated as drug delivery systems, and different film designs have been 
prepared in order to control the in vitro release of one model protein [144]. 
Overall, in this thesis it has been argued that SSP films are promising implantable 
DDS for proteins. It is now essential to investigate the described DDS as a release 
system for therapeutic biomolecules to finally assess its potential. Therefore the 
last part of this work focuses on the loading of two different therapeutic proteins: 
nerve growth factor and erythropoietin. The majority of this study consisted in the 
chromatographic analysis of the two molecules upon release from the DDS in 
order to collect first evidence of any changes occurring after the loading process.  
 
6.2. Methods 
6.2.1. Remote Loading of Nerve Growth Factor (NGF) on Spider 
Silk Films  
SSP films cast with the film applicator Coatmaster 510 (Erichsen, Hemer, 
Germany) (Method 5.2.1, page 87) and treated with water vapor (Method 5.2.6.4, 
page 90), were weighted using the balance AT216 DeltaRange® (Mettler 
Instruments, Giessen, Swizerland). Films were transferred in 6-well plates and 1 
mL of the NGF loading solution was added to each film. The NGF loading solution 
was prepared dialyzing the original nerve growth factor solution against a 10 mM 
PBS buffer pH 7. Afterwards, the solution was filtered through 0.2 µm 
polyethersulfone (PES) filter. Protein concentration was determined 
photometrically at 280 nm using the NanoDrop 2000 (Peqlab, Erlangen, 
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Germany). The extinction coefficient used in this part of the study was: E1 mg/mL 
(280 nm) = 1.5 [188]. The concentration of NGF was finally adjusted to 0.25 
mg/mL using the same dialysis buffer. Spider silk films were incubated with the 
NGF solution for 30 minutes at room temperature at 30 rpm. Later, films were 
removed from the 6-well plates and the un-loaded growth factor content in 
solution was analyzed by SEC-HPLC. The Dionex HPLC system (ASI 100, P 680, RF 
2000, Dionex Softron GmbH, Germering, Germany) was equipped with the size 
exclusion column YMC-Pack Diol-120 (YMC Europe GmbH, Dinslaken, Germany). 
The mobile phase consisted of 200 mM potassium phosphate and 450 mM 
potassium chloride, pH 7. 50 µL of each sample were injected by the auto sampler 
ASI-100 (Dionex Softron GmbH, Germering, Germany). The chromatography was 
performed with a flow rate of 0.5 mL/min. The concentration of NGF was 
calculated using a calibration curve. Data analysis was performed with 
Chromeleon® software (Dionex GmbH, Germering, Germany). The loading 
efficiency was calculated as shown in Paragraph 4.2.1, page 57. 
 
6.2.2. Direct Loading of Erythropoietin (EPO) in Spider Silk 
Films  
An erythropoietin (EPO) solution (1.9 mg/mL in 5 mM phosphate buffer pH 7.2) 
was first filtrated through a 0.2 µm PES filter. After that, the solution was 
concentrated using a Vivaspin 20 tube (MWCO 30 kDa, Sartorius, Göttingen, 
Germany) at 8000 rpm. A final EPO concentration of 5 mg/mL was obtained. 
Spider silk solution prepared according with the Method 5.2.1 (page 87) was 
mixed with the EPO solution in order to obtain 100 mg of eADF4(C16) and 2.5 mg 
EPO in 2.5 mL of casting solution containg 2% w/v of 2-pyrrolidone. This volume 
was used to cast one film following the Method 5.2.1. Films were treated with 
water vapor as described in Method 5.2.6.4, page 90. 
The therapeutic protein was analyzed by SEC-HPLC (Method 3.2.2.3, mobile phase 
listed in Table 5) and RP-HPLC (Method 3.2.2.3; mobile phase Table 5; injection 
volume 50 µL; flow 0.5 mL/min; column: YMC-Triart C18, 3 µm, 120 Å, 150 x 4.6 
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mm from YMC, Kyoto, Japan). Samples were analyzed during the manufacturing 
process, meaning: after filtration, after up-concentration with Vivaspin, and after 
the films have been incubated in 2 mL PBS at room temperature for 3 h applying 2 
rpm, in order to partially extract the therapeutic protein out of the spider silk 
matrix for the analysis.  
6.2.3. In vitro Release of Erythropoietin (EPO) encapsulated in 
Spider Silk Films  
The release of EPO was investigated from spider silk films cast manually. Films 
were prepared as described in 4.2.2. Each film contained 1.5 mg of EPO and 25 mg 
of spider silk protein. The release study was performed according to 4.2.2. RP-
HPLC for measuring protein released from the film matrix was performed using a 
Dionex Ultimate 3000 HPLC system (Dionex, Softron GmbH, Germering, Germany) 
equipped with a Jupiter 5u C4 column (300 Å, 250 mm x 4.6 mm, Phenomenex, 
Achaffenburg, Germany).  
 
6.3. Results and Discussion 
6.3.1. Loading and Release of Therapeutic Proteins 
According to the findings from paragraph 4.3.1 and 4.3.2 (pages 61-64), 
therapeutic proteins can be loaded by remote loading or direct loading giving 
their isoelectric point as shown in Figure 49. Positively charged biomolecules need 
to be remote loaded on the film surface, while negatively charged proteins can be 
directly included in the casting solution prior to casting the film. 
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Figure 49: Manufacturing steps for preparing water-based spider silk films loaded with 
therapeutic proteins using the film applicator. 
 
As a first attempt in this direction, two therapeutic proteins having different 
isoelectric points have been selected: nerve growth factor (NGF) characterized by 
an isoelectric point of 9.5 and molecular weight of 13.5 kDa [66], and 
erythropoietin (EPO), isoelectric point of 4.4 and MW of 34 kDa [189]. In 
agreement with Figure 49, NGF should be loaded by remote loading and EPO by 
direct loading. 
6.3.1.1. Remote Loading of NGF 
The primary physiological role of NGF consists in promoting and developing 
neurons in vertebrates, both sympathetic and sensory [190]. Moreover, NGF 
supports nerve regeneration and additionally it plays a role in tissue repair [191, 
192]. NGF exists mostly in its homodimer form, characterized by a dissociation 
equilibrium constant of less than 10-13 M, and is biologically active [190]. Since 
NGF has a zeta-potential of +15 mV at pH 7 [66], this protein is positively charged 
at physiological condition and should interact with the negatively charged surface 
area of e(ADF4)C16 films (paragraph 3.3.8, page 52). 
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After preparing a remote loading solution containing NGF, water-based spider silk 
films produced with the film applicator and treated with water vapor to assure 
water insolubility, were incubated in the loading solution. After removing the 
films the content of the non-loaded NGF was measured by HPLC. 
 
Figure 50: Remote loading of NGF, the bars show the area under the NGF peak measured 
by SEC-HPLC in the loading solution after the incubation with spider silk films. ‘After 
Loading 1, 2, and 3’ refer to three different spider silk films tested with the same 
condition described in Method 6.2.1. N=1 
 
The loading efficiency has been calculated to be 41.45 ± 0.7% (n= 3).  
Figure 51 shows an example of a chromatogram obtained by analyzing the protein 
NGF in the remote loading solution before and after the process. In general, 
protein physical stability in solutions can be jeopardized by interfacial interaction 
with solid surfaces [193-195], such as the one occurring during the remote 
loading. In this case, the collected chromatograms highlighted the fact that the 
protein colloidal stability has not been altered during the process since it is 
possible to recognize one single peak corresponding to the protein dimer [66] in 
both chromatograms. 
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Figure 51: SEC-HPLC chromatograms of NGF in the loading solution before (A) and after 
loading (B). 
 
In conclusion, what has been previously shown for small molecules and for one 
model protein (Lysozyme) in paragraph 4.3.1 (page 61) is in principle possible for 
therapeutic proteins as well. In general if a biomolecule is positively charged at 
the pH of the loading solution, it can be successfully loaded on the spider silk film 
surface due to electrostatic interactions. Additional work is needed in order to 
optimize the remote loading process to increase the loading efficiency. The in vitro 
release of NGF will not be presented in this work since its release kinetic depends 
on the ionic strength of the release medium (the higher the ionic strength, the 
faster the release) and on the sampling time [66]. 
 
6.3.1.2. Direct Loading of Erythropoietin in Water-based Spider Silk Films 
and in vitro Release  
Erythropoietin (EPO) is a glycoprotein mainly produced in the kidneys. The most 
important function of EPO is stimulating the proliferation and differentiation of 
red cells in the bone marrow [196]. It is clinically used in the chronical therapy of 
renal anemia [197, 198]. 
This therapeutic protein was incorporated directly in the spider silk casting 
solution, and films have been cast using this solution (Method 6.2.2). After casting, 
films were post-treated with water vapor in order to assure their water  
 
 
112 
 
insolubility (Method 5.2.6.4, page 90). A picture of SSP films cast using the film 
applicator directly loaded with EPO is represented in Figure 52.  
 
 
Figure 52: Spider silk films cast using the film applicator directly loaded with 
erythropoietin, treated with water vapor. Bar = 1 cm 
 
Figure 53 represents the qualitative analysis performed by HPLC-RP 
chromatograms of the spider silk protein e(ADF4)C16 and EPO before and after 
casting the films with the film applicator. While, Figure 54 shows examples of the 
chromatograms obtained by SEC-HPLC analysis of the same samples. 
Erythropoietin was characterized by a single peak by both chromatography 
methods, and eADF4(C16) showed two peaks by RP and two peaks with a large 
tailing by SEC analysis. The difference in the areas under the peak reported in 
Figure 53 and in Figure 54 is related to the use of two different HPLC columns. 
Overall, the chromatographic analysis suggested that the therapeutic protein was 
not negatively affected by the encapsulation and casting process. 
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Figure 53: RP-HPLC chromatograms of A: eADF4(C16) in solution after dialysis; B: 
erythropoietin in its original solution after thawing; C: erythropoietin after up-
concentration; D: eADF4(C16) (peaks 1 and 2), and erythropoietin extracted (peak 3) 
from spider silk film cast using the film applicator. 
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Figure 54: SEC-HPLC chromatograms of A: eADF4(C16) in solution after dialysis; B: 
erythropoietin in its original solution after thawing; C: erythropoietin after up-
concentration; D: eADF4(C16) (peaks 1 and 2) and erythropoietin (peak 3) extracted 
from spider silk film cast using the film applicator. 
 
The release of EPO from eADF4(C16) matrix has been studied but from films cast 
manually in order to compare the release profile with the one obtained 
encapsulating the model protein BSA in Chapter 4. Figure 56 shows that the 
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therapeutic protein is released more slowly than BSA. Overall the release profile of 
EPO (Figure 56) resembled the one of the model protein BSA but interestingly, the 
quantity of EPO released in the time considered was 10 times lower.  
 
Figure 55: Cumulative release of erythropoietin and the model protein BSA from spider 
silk films cast manually containing 1% of 2-pyrrolidone. 
 
  
Figure 56: Left: cumulative release of erythropoietin from spider silk films cast manually 
containing 1% of 2-pyrrolidone. Right: Cumulative release plotted against the square root 
of time. 
This data suggests the need to further study the interaction of biomolecules with 
the spider silk matrix. If the fraction of the released protein is plotted against the 
square root of the time, a straight line with R2= 0.995 is obtained as showed in 
Figure 56. Proposing that the release profile can be described by the Higuchi 
model [165, 199] as it was observed previously for BSA [144]. 
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This first study showed encouraging results, additional work should consider the 
encapsulation of different biomolecules and the study of their interaction with the 
spider silk protein matrix to better elucidate the in vitro release mechanism. 
Furthermore the activity of the therapeutic protein should be assessed after its 
release in order to guarantee the compatibility with the manufacturing process.  
Table 18 lists therapeutic peptides and proteins characterized by an isoelectric 
point in the range of 4-6, and therefore compatible with the direct loading process 
described in this thesis.  
Table 18: Proteins and peptides candidates compatible with the direct loading process 
Biopharmaceutical pI 
Lepirudin  4.0 
Epoetin alfa 
4.4 
Epoetin beta 
Methoxy polyethylene glycol-epoetin beta 
Epoetin zeta 
Darbepoetin alfa 
Dornase alfa  4.6 
Exenatide  4.7 
Factor IX 
5.0 
rhu-GM-CSF  
Insulin detemir 5.1 
Galactosidase alfa 
5.2 
Galactosidase beta 
Growth hormone (GH) 
5.3 
Pegvisomant  
Recombinant human insulin 
5.4 
Insulin lispro 
Anakinra  5.5 
Filgrastim 
5.6 
PEG-Filgrastim  
Interferon alfacon-1 
6.0 
Interferon-alfa-2a 
PEG-Interferon-alfa-2a 
Interferon-alfa-2b 
PEG-Interferon-alfa-2b 
Factor VIIa 6.1 
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6.4. Conclusion 
 
In this chapter water-based spider silk films prepared using the film applicator 
were loaded with two different therapeutic proteins: nerve growth factor and 
erythropoietin. The first protein was loaded by remote loading, while the second 
one by direct loading.  
The analysis of the two molecules before and after the different loading process 
did not highlight any changes occurring in the chromatograms, suggesting that 
both film casting and loading procedures were compatible with the two 
therapeutic proteins. Interestingly, the in vitro release profile of erythropoietin 
from manual cast films was found to be comparable with the one previously 
described for the model protein BSA but ten times slower. 
Additional work should consider the loading of different biomolecules and the 
investigation of their interaction with the spider silk protein matrix. Another 
aspect that should be addressed in the future consists in the study of the long term 
stability of water-based spider silk films and of the encapsulated drugs.  
Ultimately, these novel DDS must show the ability to preserve their characteristics 
as well as the ones of the incorporated drug. 
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7. Summary and Conclusion 
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Spider silk proteins represent exceptional natural polymers due to their 
mechanical properties in combination with biocompatibility. As both hydrophobic 
and slowly biodegrading biopolymers, recombinant spider silk proteins fulfill the 
required properties for a drug delivery system. The recombinant production of 
spider silk proteins allows the cost-effective fabrication of these biopolymers.  
The main focus of this thesis was to obtain a reproducible all-aqueous protein film 
production process in order to cast spider silk films characterized by 
biocompatibility, water insolubility and good mechanical properties. The 
evaluation of spider silk films as novel carrier for various pharmaceuticals was 
also part of this work. Ideally, the film preparation process has to be compatible 
with protein encapsulation and the obtained matrix should be able to release a 
therapeutic protein for a prolonged time.  
Chapter 1 discussed the use of biomaterial in drug delivery and introduced the 
properties of spider silk proteins, while Chapter 2 presented the material used in 
this project.  In Chapter 3, the preparation of eADF4(C16) films without the use of 
any organic solvent was demonstrated. Transparent water-based spider silk films 
with a homogeneous morphology and a smooth surface were obtained. The 
average thickness of the films was about 30 µm. The film surface resulted to be 
tight and compact; no visible pores were highlighted by SEM pictures. Films were 
characterized by a high content of β-sheet protein structures, which led to water 
insolubility and to a high elastic modulus. It was found that the elongation of films 
can be increased by adding small hydrophilic plasticizers in the casting 
formulation. Overall, films cast from a water solution containing glycerol or 2-
pyrrolidone were easy to handle and were characterized by a higher elongation 
than poly(l-lactic acid) films and by a maximal tensile strength comparable with 
ultra-high-molecular-weight polyethylene films. The film manufacturing method 
used in this chapter ensured water insolubility. Thus, films did not require to be 
further treated with methanol as described in the past [143, 146, 147, 152]. 
Moreover, thermal analysis highlighted the excellent thermal stability of the 
spider silk films (up to 200°C). This could be relevant for several future technical 
applications as it allows steam sterilization.   
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Chapter 4 included the evaluation of spider silk films as drug delivery matrices for 
both small molecular weight drugs and high molecular weight molecules such as 
proteins. Films were loaded with a variety of molecules (phenol red, paracetamol, 
ethacridine-lactate, nipagin, tetracaine hydrochloride, lysozyme, dextran, and 
albumin–fluorescein isothiocyanate conjugate) exploring two different loading 
techniques: remote loading and direct loading. The remote loading was found to 
be feasible for those drugs having a high logP and a strong opposite charge from 
the spider silk protein. On the contrary, the direct loading was only applicable to 
those drugs that do not interact with the spider silk protein in solution. Therefore, 
therapeutic proteins characterized by a similar isoelectric point to spider silk 
protein are suitable candidates for the direct loading method. 
During the investigation of spider silk films as drug delivery matrices, different 
film designs were prepared creating a drug delivery platform composed by spider 
silk monolayer, coated monolayer, multilayer (sandwich), and coated multilayer, 
as shown in Figure 57.  
 
 
Figure 57: Graphical summary, spider silk films as a platform for drug delivery.  
 
Monolayer water-based spider silk films can be used to achieve a prolonged 
release for large molecules (>30 kDa). The in vitro release profile was 
characterized by around 30% burst on day 1, and after that spider silk films 
released the protein BSA in a constant amount per day. Improvements in the film’s 
mechanical properties incorporating glycerol in the film matrix led to higher 
elongation but also accelerated the release of the model protein BSA. On the 
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contrary, the use of 2-pyrrolidone as a plasticizer resulted in a burst of 
approximately 20% and a steady release of the protein over 30 days.  
To further reduce the burst release occurring at day one, the monolayer films 
were coated with concentrated spider silk solution obtaining coated monolayers. 
On the one hand, this resulted in a decrease of the burst release of BSA (from 50% 
to 21%) and in a prolonged release of the model protein to over 90 days for films 
containing glycerol. On the other hand, the in vitro release profile of BSA from 
coated films containing 2-pyrrolidone was not affected. 
For the third film design a new method to prepare multilayer films was developed. 
In this manufacturing process, it was possible to produce sandwich format films 
by compressing different spider silk layers with the middle layer containing 
glycerol. The in vitro release of BSA from a multi-layer system resulted to be much 
faster than the one recorded for a monolayer film without plasticizer, and it did 
not bring additional value over the first two designs.  
By coating the multilayer films, an in vitro release profile close to a zero order 
kinetic was achieved. The coating completely eliminated the burst release and the 
release of BSA was slowed down neutralizing the glycerol effect obtaining a 
release of the protein for over 40 days. In general, the production of multilayer 
films could be advantageous in cases where the quantity of the drug loaded in one 
monolayer is not sufficient to obtain a therapeutic effect, or when it is necessary to 
load different drugs in different layers. 
In conclusion, the monolayer system containing 2-pyrrolidone as plasticizer was 
evaluated to be the best drug delivery option due to the ease of preparation, good 
mechanical properties and sustained release of a protein over 90 days.  
Finally, in Chapter 4 the biodegradation in vitro of spider silk films containing 2-
pyrrolidone was considered. The enzymatic degradation of films took place in 
presence of elastase. In future, relevant in vivo studies will be necessary to better 
characterize the biodegradation mechanism of spider silk matrices and its kinetic. 
In Chapter 5, water-based spider silk films were produced using an automatic film 
applicator. These films showed a smoother and more uniform surface, compared 
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with films cast manually. The analysis of the secondary structure of eADF4(C16) 
proteins within the film matrix revealed the poor presence of β-sheet structures. 
This resulted in films which were no longer water insoluble. In order to increase 
the content in β-sheets and produce water insoluble films, different post-
treatments were investigated. Among all the tested treatments (phosphate ions, 
ethanol, steam sterilization and water vapor), water vapor was the treatment that 
provided the most promising results. Further, it has been assessed that the 
incorporation of 2-pyrrolidone in the film matrix can improve the mechanical 
properties of the spider silk films. These films can also be treated with water 
vapor in order to achieve water insolubility. In conclusion, the solvent evaporation 
method presented in Chapter 5 allowed the production of larger spider silk films. 
The scale-up production of these films could lead to the development of products 
such as scaffolds for tissue engineering, implantable drug delivery systems, and 
coatings for implants with improved biocompatibility.  
Finally, Chapter 6 considered the loading of two different therapeutic proteins: 
nerve growth factor and erythropoietin. The first protein was loaded by remote 
loading, while the second one by direct loading. Since no stability issues were 
highlighted by the analysis, it was determined that the film casting and loading 
procedures were compatible with therapeutic proteins.  
In conclusion, the results in this thesis indicate that spider silk films are a 
promising biodegradable protein drug delivery matrix, capable of releasing a 
model protein over 90 days. Such films could be used for several pharmaceutical 
and medical purposes, especially when mechanical strength of a drug eluting 
matrix is of high importance. Additional work would be needed in order to bring a 
final drug release system made of spider silk to market, however this thesis 
demonstrates that this rather new biomaterial has the necessary prerequisites to 
become a benchmarked polymer for medical applications.  
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[154] Borkner CB, Wohlrab S, Möller E, Lang G, Scheibel T. Surface modification of 
polymeric biomaterials using recombinant spider silk proteins. ACS Biomaterials 
Science & Engineering. 2016 (article ASAP). 
[155] Technologies L. SilverXpress® Silver Staining Kit Protocol. 2012;Catalog 
number LC6100  
[156] Winston PW, Bates DH. Saturated Solutions For the Control of Humidity in 
Biological Research. Ecology. 1960;41:232-7. 
[157] Martin P. Neubauer CB, Elisa Agostini, Julia Engert, Thomas Scheibel and 
Andreas Fery. Micromechanical characterization of spider silk particles. 
Biomaterials Science. 2013; 1160:1165-1. 
[158] Lucke M, Winter G, Engert J. The effect of steam sterilization on recombinant 
spider silk particles. International Journal of Pharmaceutics. 2015;481:125-31. 
 
142 
 
[159] Kevin D. Hermansona MBH, Thomas Scheibel and Andreas R. Bausch. 
Permeability of silk microcapsules made by the interfacial adsorption of protein. 
Physical Chemistry Chemical Physics. 2007;9:6442-6. 
[160] Hofmann S, Wong Po Foo CT, Rossetti F, Textor M, Vunjak-Novakovic G, 
Kaplan DL, et al. Silk fibroin as an organic polymer for controlled drug delivery. 
Journal of Controlled Release. 2006;111:219-27. 
[161] Hines DJ, Kaplan DL. Mechanisms of controlled release from silk fibroin 
films. Biomacromolecules. 2011;12:804-12. 
[162] Lu S, Wang X, Lu Q, Zhang X, Kluge JA, Uppal N, et al. Insoluble and flexible 
silk films containing glycerol. Biomacromolecules. 2010;11:143-50. 
[163] Wilson D, Valluzzi R, Kaplan D. Conformational Transitions in Model Silk 
Peptides. Biophysical Journal.78:2690-701. 
[164] Park K. Controlled drug delivery systems: Past forward and future back. 
Journal of Controlled Release. 2014;190:3-8. 
[165] Higuchi T. Mechanism of sustained-action medication. Theoretical analysis 
of rate of release of solid drugs dispersed in solid matrices. Journal of 
Pharmaceutical Sciences. 1963;52:1145-9. 
[166] Peppas NA, Narasimhan B. Mathematical models in drug delivery: How 
modeling has shaped the way we design new drug delivery systems. Journal of 
Controlled Release. 2014;190:75-81. 
[167] Fu K, Pack DW, Klibanov AM, Langer R. Visual Evidence of Acidic 
Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres. 
Pharm Res. 2000;17:100-6. 
 
143 
 
[168] Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS. Injectable 
controlled release depots for large molecules. Journal of Controlled Release. 
2014;190:240-53. 
[169] Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Progress in 
Polymer Science. 2007;32:762-98. 
[170] Franz S, Rammelt S, Scharnweber D, Simon JC. Immune responses to 
implants – A review of the implications for the design of immunomodulatory 
biomaterials. Biomaterials. 2011;32:6692-709. 
[171] Pamula E, Menaszek E. In vitro and in vivo degradation of poly(l-lactide-co-
glycolide) films and scaffolds. Journal of Materials Science: Materials in Medicine. 
2008;19:2063-70. 
[172] Lu L, Peter SJ, D. Lyman M, Lai H-L, Leite SM, Tamada JA, et al. In vitro and in 
vivo degradation of porous poly(dl-lactic-co-glycolic acid) foams. Biomaterials. 
2000;21:1837-45. 
[173] Jin HJ, Park J, Karageorgiou V, Kim UJ, Valluzzi R, Cebe P, et al. Water-Stable 
Silk Films with Reduced β-Sheet Content. Advanced Functional Materials. 
2005;15:1241-7. 
[174] Lawrence BD, Wharram S, Kluge JA, Leisk GG, Omenetto FG, Rosenblatt MI, 
et al. Effect of Hydration on Silk Film Material Properties. Macromolecular 
Bioscience. 2010;10:393-403. 
[175] Lammel AS, Hu X, Park S-H, Kaplan DL, Scheibel TR. Controlling silk fibroin 
particle features for drug delivery. Biomaterials. 2010;31:4583-91. 
[176] Lammel A, Schwab M, Slotta U, Winter G, Scheibel T. Processing Conditions 
 
144 
 
for the Formation of Spider Silk Microspheres. ChemSusChem. 2008;1:413-6. 
[177] Lu Q, Wang X, Hu X, Cebe P, Omenetto F, Kaplan DL. Stabilization and 
Release of Enzymes from Silk Films. Macromolecular Bioscience. 2010;10:359-68. 
[178] Wenk E, Wandrey AJ, Merkle HP, Meinel L. Silk fibroin spheres as a platform 
for controlled drug delivery. Journal of Controlled Release. 2008;132:26-34. 
[179] Taketani I, Nakayama S, Nagare S, Senna M. The secondary structure control 
of silk fibroin thin films by post treatment. Applied Surface Science. 
2005;244:623-6. 
[180] Nogueira GM, Rodas ACD, Leite CAP, Giles C, Higa OZ, Polakiewicz B, et al. 
Preparation and characterization of ethanol-treated silk fibroin dense membranes 
for biomaterials application using waste silk fibers as raw material. Bioresource 
Technology. 2010;101:8446-51. 
[181] Chen X, Shao Z, Knight DP, Vollrath F. Conformation transition kinetics of 
Bombyx mori silk protein. Proteins: Structure, Function, and Bioinformatics. 
2007;68:223-31. 
[182] EMA. Decision tree for the selection of sterilization methods 
(CPMP/QWP/054/98). 2000. 
[183] Menzen T, Friess W, Niessner R, Haisch C. Laser-induced breakdown 
detection of temperature-ramp generated aggregates of therapeutic monoclonal 
antibody. European Journal of Pharmaceutics and Biopharmaceutics. 
2015;94:463-7. 
[184] Menzen T, Friess W. Temperature-Ramped Studies on the Aggregation, 
Unfolding, and Interaction of a Therapeutic Monoclonal Antibody. Journal of 
 
145 
 
Pharmaceutical Sciences. 2014;103:445-55. 
[185] Menzen T, Friess W. High-throughput melting-temperature analysis of a 
monoclonal antibody by differential scanning fluorimetry in the presence of 
surfactants. Journal of Pharmaceutical Sciences. 2013;102:415-28. 
[186] Hino T, Tanimoto M, Shimabayashi S. Change in secondary structure of silk 
fibroin during preparation of its microspheres by spray-drying and exposure to 
humid atmosphere. Journal of Colloid and Interface Science. 2003;266:68-73. 
[187] Hu X, Shmelev K, Sun L, Gil E-S, Park S-H, Cebe P, et al. Regulation of Silk 
Material Structure by Temperature-Controlled Water Vapor Annealing. 
Biomacromolecules. 2011;12:1686-96. 
[188] Rattenholl A, Lilie H, Grossmann A, Stern A, Schwarz E, Rudolph R. The 
pro‐sequence facilitates folding of human nerve growth factor from Escherichia 
coli inclusion bodies. European Journal of Biochemistry. 2001;268:3296-303. 
[189] Lai P, Everett R, Wang F-F, Arakawa T, Goldwasser E. Structural 
characterization of human erythropoietin. Journal of Biological Chemistry. 
1986;261:3116-21. 
[190] Greene L, Shooter E. The nerve growth factor: biochemistry, synthesis, and 
mechanism of action. Annual review of neuroscience. 1980;3:353-402. 
[191] Lee AC, Yu VM, Lowe JB, Brenner MJ, Hunter DA, Mackinnon SE, et al. 
Controlled release of nerve growth factor enhances sciatic nerve regeneration. 
Experimental neurology. 2003;184:295-303. 
[192] Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, et al. Nerve 
growth factor displays stimulatory effects on human skin and lung fibroblasts, 
 
146 
 
demonstrating a direct role for this factor in tissue repair. Proceedings of the 
National Academy of Sciences. 2001;98:6162-7. 
[193] Jorgensen L, Bennedsen P, Hoffmann SV, Krogh RL, Pinholt C, Groenning M, 
et al. Adsorption of insulin with varying self-association profiles to a solid Teflon 
surface—Influence on protein structure, fibrillation tendency and thermal 
stability. European Journal of Pharmaceutical Sciences. 2011;42:509-16. 
[194] Vermeer AWP, Giacomelli CE, Norde W. Adsorption of IgG onto hydrophobic 
teflon. Differences between the Fab and Fc domains. Biochimica et Biophysica Acta 
(BBA) - General Subjects. 2001;1526:61-9. 
[195] Bee JS, Randolph TW, Carpenter JF, Bishop SM, Dimitrova MN. Effects of 
surfaces and leachables on the stability of biopharmaceuticals. Journal of 
Pharmaceutical Sciences. 2011;100:4158-70. 
[196] Bittner B, Morlock M, Koll H, Winter G, Kissel T. Recombinant human 
erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence 
of the encapsulation technique and polymer purity on microsphere 
characteristics. European Journal of Pharmaceutics and Biopharmaceutics. 
1998;45:295-305. 
[197] Morlock M, Kissel T, Li YX, Koll H, Winter G. Erythropoietin loaded 
microspheres prepared from biodegradable LPLG–PEO–LPLG triblock 
copolymers: protein stabilization and in-vitro release properties. Journal of 
Controlled Release. 1998;56:105-15. 
[198] Morlock M, Koll H, Winter G, Kissel T. Microencapsulation of rh-
erythropoietin, using biodegradable poly(d,l-lactide-co-glycolide): protein 
stability and the effects of stabilizing excipients. European Journal of 
Pharmaceutics and Biopharmaceutics. 1997;43:29-36. 
 
147 
 
[199] Siepmann J, Peppas NA. Higuchi equation: Derivation, applications, use and 
misuse. International Journal of Pharmaceutics. 2011;418:6-12. 
 
